Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2018

Effects of MenAfriVac® Introduction in the African
Meningitis Belt, 2010-2017
Andre Arsene Bita Fouda
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Epidemiology Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been
accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please
contact ScholarWorks@waldenu.edu.

Walden University
College of Health Sciences

This is to certify that the doctoral dissertation by

Andre Arsene Bita Fouda

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.

Review Committee
Dr. German Gonzalez, Committee Chairperson, Public Health Faculty
Dr. Namgyal Kyulo, Committee Member, Public Health Faculty
Dr. Jagdish Khubchandani, University Reviewer, Public Health Faculty

Chief Academic Officer
Eric Riedel, Ph.D.

Walden University
2018

Abstract
Effects of MenAfriVac® Introduction in the African Meningitis Belt, 2010-2017
by
Andre Arsene Bita Fouda

MD, University of Yaounde 1, 1999
MPH, Walden University, 2015

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy
Public Health

Walden University
August 2018

Abstract
Meningococcal meningitis is a burden in the African meningitis belt. Before 2010,
Neisseria meningitidis serogroup A (N. meningitidis A) was the predominant pathogen
causing deathly epidemics. MenAfriVac® vaccine protects against N. meningitidis A. It
was introduced in 2010 into highest meningitis risk health districts. There was limited
data on the effects of MenAfriVac®, mainly on the degree of relationship between N.
meningitidis A and the MenAfriVac® immunization. The social ecological model was
used as a theoretical framework for this study. The purpose of this quantitative study was
to assess the effectiveness of MenAfriVac® from 2010 to 2017 in 21 out of 26 countries
of the African meningitis belt. The four research questions contributed to establishing the
effects of MenAfriVac®. An interrupted time series design and nonprobability sampling
were used. Secondary data were retrieved from World Health Organization database. The
binomial negative regression and Pearson’s Chi-Square tests were used. The study found
that after the MenAfriVac® introduction there were 39% decline of incidence rate of the
meningitis suspected cases (IRR 0.61, 95% CI 0.48 – 0.79, p < .001), a high degree of
relationship between N. meningitidis A and MenAfriVac® immunization (χ2 (1) =
11039.49, p = 0.000, Phi = 0.657, P=0.000), 99% decline of the risk of N. meningitidis A
(RR 0.01, 95% CI 0.08-0.013), and 99.6% decline of risk of epidemic due to N.
meningitidis A (RR 0.004, 95% CI 0.001-0.016). The study demonstrated that
high MenAfriVac® coverage and enhanced surveillance are pivotal to reduce the
meningitis burden. Results will be used to inform policy and public health practice to
reduce the meningitis cases and improve quality of live in the community.
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Chapter 1: Introduction to the Study
Introduction
Meningococcal meningitis is a major public health problem in 26 countries that
have the highest rates of the disease in the African meningitis belt, stretching from
Senegal in the west to Ethiopia in the east (World Health Organization [WHO], 2015a).
The meningococcal meningitis is a bacterial form of meningitis, a serious infection of the
meninges, thin fibrous tissue that covers the brain and spinal cord. It can cause severe
brain damage and is fatal in 50% of cases if left untreated (WHO, 2015a, WHO, 2015b,
Kiefer, 2016). Before 2010, Neisseria meningitidis serogroup A (N. meningitidis A) was
the predominant cause of meningitis epidemics, and it accounts for almost 80%-85% of
meningitis outbreaks. The meningococcal conjugate A vaccine called MenAfriVac®
prequalified by WHO was developed by Serum Institute of India. This new vaccine is
being introduced in countries of the meningitis belt to eliminate meningococcal
meningitis caused by N. meningitidis A (WHO, 2015a; Tiffay, Jodar, Kieny, Socquet, &
Laforce, 2015).
Few studies showed the early effects of the introduction of MenAfriVac® in 15
countries using the carriage, surveillance, and determination of antibodies provided by
the new vaccine. In this study, I considered 21 out of 26 of meningitis belt countries.
Meningitis enhanced surveillance has been enhanced since 2002 in the meningitis belt. In
preparation for the introduction of MenAfriVac®, an enhanced meningitis surveillance
network was established by WHO. Meningitis enhanced surveillance aims to assess the
effects of the introduction of new vaccines, to detect and confirm epidemics and launch
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appropriate response strategies, to assess case burden and incidence trends, to monitor the
antibiotic resistance profile of N. meningitidis, including N. meningitidis A or other
pathogens, and to monitor the circulation, distribution, and evolution of N. meningitidis
serogroups and other pathogens (WHO, 2014a). I used enhanced surveillance as an
instrument of measurement in this study. For this study, I considered the longest period
and more countries than the study conducted previously. The estimation of
MenAfriVac® protection is ten years. Therefore, studying effects including protection
more years after the first introduction is relevant. This study also aimed to show that
meningococcal meningitis caused by other serogroups than N. meningitidis A remains a
burden in the African meningitis belt. The use of meningitis enhanced surveillance is
relevant because it helps not only to detect epidemics earlier but also to control the
elimination of disease within all health areas at high risk of N. meningitidis A. The
reasons to conduct this study can be explained by the needs of use of another
measurement method such as enhanced surveillance that is feasible in all health areas as a
routine activity with low cost. The number of countries concerned in this study is higher
than in previous studies, and therefore the generalizability of findings is greater. Findings
on crude fatality rate (CFR) and the degree of relationship between N. meningtitidis A
and MenAfriVac® are insufficient in the literature. For the reasons stated above, this
study contributed to reducing the gap in the literature on the effects of the introduction of
MenAfriVac® in the African meningitis belt.
The potential positive social change is the reinforcement of public health policies,
especially on surveillance and immunization, to achieve the elimination of vaccine-
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preventable diseases. The high level of MenAfriVac® coverage and the quality of
meningitis enhanced surveillance might be two relevant factors in achieving the
elimination of N. meningitidis A. In addressing and emphasizing these factors; sought in
this study to create a positive social change with the strengthening of immunization and
surveillance policies.
This chapter presents the background of the study, problem statement, purpose of
the study, and research questions. This chapter also includes the theoretical framework,
the nature of the study, definition of terms, and assumptions, scope, limitations, and
significance of the study.
Background of the Study
Meningococcal disease is a leading cause of bacterial meningitis and sepsis, and a
major cause of epidemics. It is a very serious disease with a fatality rate of 50% if left
untreated. The common risk factors are age between 1 to 29 years old, community
setting, environment, and travel. The findings showed that meningococcal meningitis has
the greatest incidence with large epidemics in Africa in the dry season (Centers for
Disease Control and Prevention [CDC], 2014; Greenwood, 1999; Lapeyssonnie, 1963;
Molesworth, Cuevas, Connor, Morse, & Thomson, 2003;). N. meningitidis is transmitted
from person-to-person through droplets of respiratory or throat secretions from carriers.
Ten percent to 20% of the population carries N. meningitidis in their throat at any given
time (WHO, 2014b, WHO, 2015b).
By far the highest incidence of meningococcal disease occurs in the meningitis
belt of sub-Saharan Africa. During epidemics, the incidence can approach 1,000 per
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100,000, or 1% of the population (CDC, 2014; CDC, 2015a; Harrison et al., 2009; Kiefer,
2016; National Institute of Health. [NIH], 2016; WHO, 2015a, WHO, 2015b). Of the 12
serogroups of N. meningitidis identified, four serogroups, A, B, C, and W135, are
recognized to be the main causes of epidemics. Meningococcal meningitis cases occur
throughout the world. Before the introduction of MenAfriVac® in 2010, N. meningitidis
A accounted for an estimated 80%–85% of all cases in the African meningitis belt, with
epidemics occurring at intervals of 7–14 years. The African meningitis belt stretches
from Senegal in the west to Ethiopia in the east and includes 26 countries where an
estimated 450 million people are living (CDC, 2015a; Nicolas, 2012; Programme for
Appropriate Technology Health [PATH], 2016a; WHO, 2015a; WHO 2015b; WHO,
2017, March 13).
The largest meningococcal meningitis epidemic was reported in 1996 and 1997,
where more than 25,000 people died and more than 250,000 were affected. Following
this devastating epidemic, African leaders called for the development of an affordable
vaccine that would eliminate N. meningitidis A epidemics in Africa (Aguado et al., 2015;
Nicolas, 2012; PATH, 2016a; PATH, 2016b; Vergnano & Health, 2003). An affordable
monovalent MenA polysaccharide-tetanus toxoid conjugate vaccine called MenAfriVac®
was developed and prequalified in 2009 by WHO. MenAfriVac® has been introduced in
African meningitis belt countries since 2010 (Frasch, Preziosi, & LaForce, 2012; Idoko et
al., 2014). Only the health districts that are at highest risk were selected to introduce
MenAfriVac®. The selection was made through the risk assessment using the district
prioritization tool developed by WHO (Cibrelus, Lingani, Fernandez, Perea, & Hugonnet,
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2015). MenAfriVac® vaccine can provide herd and individual protection when a health
district has reached at least 90% of administrative coverage or 70% of immunization
coverage during a mass vaccination campaign. Between 2010 and 2017, 21 countries
have introduced MenAfriVac® with over 260 million people vaccinated aged 9 months
to 29 years through mass vaccination campaigns and routine vaccination programmes
(Djingarey et al., 2012; Djingarey et al., 2015; WHO, 2017, March 13).
The early effects are being found by some authors. The global reduction of the
incidence and occurrence of meningitis epidemics caused by N. meningitidis A in the
meningitis belt were shown by PATH (2016d), PATH and WHO (2016), and WHO
(2014d, 2015b, 2016b, 2017),. Specifficly, Novak et al. (2012) showed 71% decline in
risk of meningitis (suspected cases) and >99% decline in risk of N. meningitidis A
(confirmed cases) in Burkina Faso 1 year after the introduction of MenAfriVac®. Daugla
et al. (2013) found a 94% reduction in the incidence of meningitis in a vaccinated
population and 98% decrease in N. meningitidis A carriage prevalence within 4–6 months
after MenAfriVac® mass vaccination campaign. A study by Trotter et al. (2017) in nine
countries (Benin, Burkina Faso, Chad, Côte d’Ivoire, Ghana, Mali, Niger, Nigeria, Togo)
showed a 58% decline in incidence of meningitis (suspected cases), > 99% decline in
incidence of N. meningitidis A (confirmed cases), and 60% decline in epidemics risk of a
district reaching the epidemic threshold. Kristiansen et al. (2013) found the effectiveness
of MenAfriVac® on the carriage of N. meningitidis A among persons vaccinated in
Burkina Faso 2 years after a MenAfriVac® mass vaccination campaign. The study was
needed to fill the gap of the literature, especially on the relationship between
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MenAfriVac® introduction and the CFR and the level of relationship between N.
meningitidis A and MenAfriVac® immunization. This study was also needed to fill the
gap on the effects of MenAfriVac® several years after its introduction and in considering
many countries for relevant generalizability.
Problem Statement
Meningococcal meningitis remains a public health problem in the 26 high-risk
countries situated in the African meningitis belt. Before 2010, N. meningitidis A
represented between 80% and 85% of meningitis infections. Following the deadliest
meningitis epidemics in 1996-97, MenAfriVac® was developed. MenAfriVac® provided
people who were vaccinated individual protection and reduced the carriage of N.
meningitidis A and, therefore, increased the herd immunity (WHO, 2015a). According to
WHO (2017, March 13), by 2016, 260.6 million people aged 1-29 years old were
vaccinated with MenAfriVac® through preventive campaigns in 19 countries: Benin,
Burkina Faso, Cameroon, Chad, Cote d’Ivoire, Democratic Republic of Congo, Ethiopia,
Gambia, Ghana, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Nigeria, Senegal,
South Sudan, Sudan, and Togo.
The objective of this study was to assess the effects of the introduction of
MenAfriVac® in the 21 out of 26 countries of the African meningitis belt. Few studies
conducted previously evaluated the early effects of MenAfriVac®. These studies showed
a decrease in the incidence of meningococcal meningitis after the introduction of
MenAfriVac® (Djingarey et al., 2012; Kristiansen, 2013; Novak et al., 2012; Diomandé
et al., 2015). However, the gap in the literature was significant, especially regarding the
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relationship between MenAfriVac® introduction and the CFR and the level of
relationship between N. meningitidis A and MenAfriVac® immunization. This study
evaluated the effectiveness of the introduction of MenAfriVac® in 21 countries using
meningitis enhanced surveillance data from 2004 to 2017. This multi-country study
involved 21 countries with the population living in the 1,713 meningitis highest risk
health districts. It helped to assess more years protection provided by MenAfriVac® and
showed the risk of the occurrence of meningococcal meningitis due to serogroups other
than N. meningitidis A. The generalizability of the results of this study was relevant. The
study also assessed the risk of meningitis due to other meningococcal serogroups through
analyses of occurrence of epidemics, incidence, and mortality of meningococcal
meningitis before and after 2010.
Purpose Statement
The research purpose of this quasi-experimental and quantitative study was to
assess the effectiveness of the introduction of a new meningococcal conjugate A vaccine
called “MenAfriVac®” in 21 countries of the meningitis belt from 2010 to 2017. I
retrieved secondary data from meningitis surveillance between 2004 and 2017 and
MenAfriVac® immunization between 2010 and 2017 to complete the study. This study
compared the risk of meningitis disease, deaths, and occurrence of epidemics before and
after MenAfriVac® introduction. Incident rate ratio (IRR) of meningitis suspected and
fatal meningitis was calculated using the negative binomial regression. I calculated
Pearson’s Chi-Square test to estimate the relative risk of CFR, N. meningitidis A
confirmed cases (N. meningitidis A and non-N. meningitidis A), and I estimated the
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frequency of epidemics due to N. meningitidis A in MenAfriVac® vaccinated and
unvaccinated populations. The dependent variables selected were occurrence of N.
meningitidis A or not (another pathogen than N. meningitidis A, negative cerebrospinal
fluid [CSF] sample), meningitis suspected cases, deaths, and the occurrence of meningitis
epidemics. The independent variable was MenAfriVac® vaccination status of health
district (vaccinated after the introduction of MenAfriVac®; vaccinated with any other
polysaccharide vaccine that includes antigen A; unvaccinated before the introduction of
MenAfriVac®). Pathogens were isolated from CSF samples by culture or detected by
latex agglutination test or polymerase chain reaction (PCR). CSF samples were
transported from healthcare facilities to the district or national reference laboratories that
conduct laboratory testing.
Research Questions and Hypotheses
The four research questions (RQ) were developed to assess the effects of
MenAfriVac® introduction in the 21 out of 26 African meningitis countries between 2010
and 2017. The null hypotheses (H0) and alternatives hypotheses (Ha) defined below
related to each RQ. These hypotheses were tested using inferential statistics to assess the
effects of MenAfriVac® by establishing the strength of the relationship between
immunization with MenAfriVac® of people living in high-risk meningitis districts and the
reduction of occurrence of meningitis suspected cases, deaths, and health districts in
epidemic due to N. meningitidis A. The RQs and hypotheses were as follows:
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RQ1: What is the difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26 countries
of African meningitis belt between 2010 and 2017?
H01: There is no difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26
countries of African meningitis belt between 2010 and 2017.
Ha1: There is a difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26
countries of African meningitis belt between 2010 and 2017.
RQ2: What is the difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis belt
between 2010 and 2017?
H02: There is no difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis
belt between 2010 and 2017.
Ha2: There is the difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis
belt between 2010 and 2017.
RQ3: What is the degree of relationship between the incidence of Neisseria
meningitidis serogroup A and the MenAfriVac® immunization in 21 out of the 26
countries of African meningitis belt between 2010 and 2017?
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H03: There is no relationship between the incidence of Neisseria meningitidis
group A and the MenAfriVac® immunization in 21 out of the 26 countries of
African meningitis belt between 2010 and 2017.
Ha3: There is a relationship between the incidence of Neisseria meningitidis A
and the MenAfriVac® immunization in 21 out of the 26 countries of African
meningitis belt between 2010 and 2017.
RQ4: What is the difference in the frequency of meningitis epidemics caused by
Neisseria meningitidis A before and after the MenAfriVac® introduction in 21 out
of the 26 countries of African meningitis belt?
H04: There is no difference in the frequency of meningitis epidemics caused
by Neisseria meningitidis A before and after the MenAfriVac® introduction in
21 out of the 26 countries of African meningitis belt.
Ha4: There is the difference in the frequency of meningitis epidemics caused
by Neisseria meningitidis A before and after the MenAfriVac® introduction in
21 out of the 26 countries of African meningitis belt.
Theoretical Framework
The social ecological model (SEM) was a theoretical framework for prevention
used in this research dissertation. According to CDC (2015b), the SEM is a theory-based
framework that can be used to better understand the effect of potential prevention
strategies such as immunization because it is a framework for prevention. SEM
comprises multiple-level approaches that are individual, relationship, community,
organizational, and policy levels. All these approaches fit with the risk factors of
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meningococcal meningitis and the public health interventions that are being
implemented. Prevention using immunization and public health policies were built by
countries to provide individual protection and herd immunity against N .meningitidis A.
The SEM is based on evidence that no single factor can explain why some people
or groups are at higher risk for meningococcal meningitis while others are more protected
from it. This framework views protection with MenAfriVac® as the outcome of
interaction among many factors. These factors are the individual, the relationship, the
community, and the societal levels. Therefore this framework was related to the research
questions that sought to show the effectiveness of the protection provided by
MenAfriVac® to individual and community. Concerning especially the societal level, it is
characterized by the quality of the public health policy used to organize immunization
campaigns and routine programs with the involvement of the health institutions and
researchers to contribute to the achievement of the elimination of meningococcal
meningitis due to N. meningitidis A.
Nature of the Study
The study was quasi-experimental research, and an interrupted time series
quantitative research design. I used the interrupted times series design to assess the effect
of the introduction of the MenAfriVac® in 21 countries selected for this study between
2010 and 2017. Secondary data from meningitis enhanced surveillance and MenAfriVac®
immunization coverage were used for the period between 2004 and 2017. The variables
selected in this study helped to provide descriptives and inferential statistics. I chose the
negative binomial regression model and Pearson’s Chi-Square tests to assess the effects
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of MenAfriVac® introduction, especially the relationship between vaccination with
MenAfriVac® and the occurrence of meningitis suspected cases, N. meningitidis A cases,
deaths, and epidemics.
The dependent variables selected were occurrence of N. meningitidis A or not
(another pathogen than N. meningitidis A, negative CSF sample), incidence rate of
meningitis suspected cases, deaths, and the occurrence of meningitis epidemics. The
independent variable was MenAfriVac® vaccination status of health district (vaccinated
after the introduction of MenAfriVac®; vaccinated with any other polysaccharide vaccine
that includes antigen N. meningitidis A; unvaccinated before the introduction of
MenAfriVac®). I chose the period between 2004 and 2017.
Definition of Terms
Some terms were used in the study to assess the effects of MenAfriVac® in
meningitis belt below:
Alert threshold: A level of incidence that triggers action to prepare for an
epidemic, including strengthening surveillance, confirming cases, distributing treatment
protocols and informing the authorities (WHO, 2014c; WHO, 2015b).
Case definition of meningitis disease: Any person with sudden onset of fever
(>38.5 °C rectal or 38.0 °C axillary) and neck stiffness or another meningeal sign
including bulging fontanel in toddlers (WHO, 2015b).
Case fatality rate (CFR): The proportion of persons with a disease in a specified
period that dies from the disease (Johns Hopkins, International Federation of Red Cross,
& Red Crescent Societies, 2008).
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Confirmed meningitis case: Any suspected or probable case that is laboratory
confirmed by culturing or identifying (i.e., by PCR, immunochromatographic dipstick, or
latex agglutination) of Neisseria meningitidis, Streptococcus pneumoniae or
Haemophilus influenza type b in the CSF or blood (WHO, 2015b).
Effectiveness: The ability of an intervention or program to produce the intended or
expected results in the field
Epidemic threshold: A higher level of incidence that triggers an epidemic
response, including mass vaccination, antibiotic distribution, and raising public
awareness (WHO, 2014c; WHO, 2015b).
Epidemic: An increase, often sudden, in the number of cases of disease above
what is generally expected in that population in that area (CDC, 2012c).
Incidence rate ratio (IRR): A measure of the frequency with which new cases of
illness, injury, or other health conditions occur, expressed explicitly per a time frame.
Incidence: A measure of the frequency with which new cases of illness, injury, or
other health conditions occur among a population during a specified period (CDC,
2012c).
Cumulative incidence: The ratio of the number of new cases of disease to the total
number of participants who are at risk (Sullivan, 2012).
MenAfriVac® (PsA-TT, MenA, MACV): The meningococcal A conjugate
vaccine, a lyophilized vaccine of purified meningococcal serogroup A polysaccharide
(PsA) covalently bound to tetanus toxoid (TT) that acts as a carrier protein (Frasch et al.,
2012; Sambo et al., 2015; WHO, 2017a).
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Meningococcal meningitis: A bacterial disease caused by N. meningitidis. A
serious infection of the thin lining that surrounds the brain and spinal cord. It can cause
severe brain damage and is fatal in 50% of cases if untreated (WHO, 2015a, WHO,
2015b, WHO, 2017, March 13).
Mortality rate: A measure of the frequency of occurrence of death among a
defined population during a specified time interval (CDC, 2012c).
Operational threshold: Criteria that trigger specific actions to prepare for an
epidemic (the alert threshold) or respond to an epidemic (the epidemic threshold) in
health districts, subdistricts, or populations at risk (WHO, 2014c).
Relative risk (RR): The ratio of prevalence or incidence in the exposed group to
the prevalence or incidence in the unexposed group. (Sullivan, 2012).
Surveillance: The ongoing systematic collection, analysis, and interpretation of
health data (WHO, 2010).
Suspected case (of meningitis): Any person with sudden onset of fever (> 38.5o C
rectal or > 38.0o C axillary) and one of the following signs: neck stiffness, flaccid neck,
bulging fontanelle, convulsion, or other meningeal signs (WHO, 2014c).
The key pillars strategy or the control of epidemic meningitis: Surveillance,
treatment and care, and vaccination (WHO, 2015b).
The African meningitis belt: Stretches from Senegal in the west to Ethiopia in the
east. It is constituted by 26 countries: Benin, Burkina Faso, Burundi, Cameroon, Chad,
Centre African Republic, Cote d’Ivoire, Democratic Republic of Congo, Eritrea,
Ethiopia, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Mali, Mauritania, Niger,
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Nigeria, Rwanda, Senegal, South Sudan, Sudan, Tanzania, Togo, and Uganda (WHO,
2015a).
Vaccine effectiveness: The ability of the vaccine to prevent outcomes of interest
(McNeil, 2006).
Assumptions
Four assumptions were retained for this dissertation research. These assumptions
focused on the relevance of the surveillance, the accuracy of data retrieved from WHO
databases. The fourth assumption focused also on the fact that meningococcal meningitis
remains a public health problem despite the introduction of MenAfriVac®. What follows
are the four assumptions explained.
The first assumption was that surveillance is a relevant instrument measure to
evaluate the effects of the introduction of a new vaccine such as MenAfriVac®. The goals
of meningococcal surveillance are: to detect outbreaks of meningococcal disease so that
appropriate control measures can be promptly instituted. Secondly, to assess changes in
the epidemiology of meningococcal disease over time to permit the most efficient
allocation of resources and formulation of the most effective disease control and
prevention policies. Meningococcal serogroup surveillance data are essential to monitor
and assess the impact of new vaccines. African meningitis belt countries have national
plans for integrated disease surveillance and response, which include meningitis. WHO
support countries to strengthen their disease surveillance especially meningitis. The
purpose of meningitis enhanced surveillance is to detect changing epidemiological
patterns of meningitis epidemics promptly. Also to provide evidence to guide case
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management and prompt epidemic response (MacNeil, & Cohn, 2013; WHO, 2009a,
WHO & CDC, 2010; WHO, 2015; Mueller, 2013; Harrison et al., 2009; Djingarey et al.,
2008).
WHO recommended three instrument measures to assess the effectiveness of a
new vaccine. These instrument measures are a study of the carriage, a calculation of
antibodies provided by immunization, and enhanced surveillance. Enhanced surveillance
is used at all the levels of health, and the cost is affordable. It is a routine activity carried
out by training health personnel that are often engaged in immunization activities
especially in the filed thus health district. Therefore, showing that surveillance is relevant
because of its reliability and its validity are valuable for a routine and affordable activity.
The second assumption was that the two databases of WHO IST WA are relevant
to gather secondary data respectively from meningitis surveillance and MenAfriVac®
vaccination coverage between January 2004 and December 2017. Therefore, it can be
used for the dissertation research to assess the effects of the introduction of MenAfriVac®
in 21 countries of meningitis belt. Data for meningitis surveillance as well as for
MenAfriVac® immunization activities found in the WHO Inter-country Support Team for
West Africa (WHO IST WA) databases are aggregated data sent by countries regularly
on a weekly basis. These data were gathered, treated, consolidated and validated at the
country level before sending to WHO ISTWA with the technical support of partners such
as CDC and WHO country staffs. It was essential to show their accuracy and then their
usefulness such as measuring the effects of the introduction of a new vaccine to reduce
the burden of disease such as meningitis due to N. meningitidis A.
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The third assumption was that the introduction of MenAfriVac® in Africa using
appropriate public health intervention and organization with health agencies and human
resources reduced the burden of meningococcal meningitis especially due to N.
meningitidis A. The success of any public health intervention such as immunization or
surveillance requires effective preparedness, activities, strategies planned and appropriate
resources mobilized. That seems to be the case of introduction of MenAfriVac® in Africa
that could be benchmarked in other diseases to challenging in Africa.
The fourth assumption was that meningitis disease remains a public health
problem in the African meningitis belt due to other pathogens than N. meningitidis A.
This study showed also the incidence of meningitis disease and meningitis epidemics
recorded in African meningitis belt.
The Scope of the Study
The previous studies on evaluation of early effects of MenAfriVac® were limited
in 15 countries out of 21 that introduced from 2010 to January 2017. The meningitis belt
comprises almost 450 million persons at risk (Frash et al., 2012). The time of the study
concerned the period from January 2004 to June 2017, seven years before and after the
beginning of the introduction of MenAfriVac® in 2010. This period was chosen to
measure the incidence and the occurrence of meningitis epidemic before and after the
introduction of MenAfriVac® in the 21 countries selected. Also, the health district of the
21 countries that introduced or not MenAfriVac® were considered. The pathogens
reported were considered. This rsult contributed to measuring the updated predominance
of the cause of meningitis epidemics. According to WHO (2009a), three methods of
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measurement can be used as measurement methods to demonstrate the effectiveness of
MenAfriVac® that are meningitis surveillance, find the immunity by the determination of
N. meningitidis A antibodies, and the meningococcal carriage study. In this study, the
measurement method used was meningitis enhanced surveillance. The size of the sample
used was extensive with 21 out of 26 countries of the meningitis belt selected for the
study given relevant generalizability of findings.
Limitations
For this study, the use of secondary data was one of the limitations because of the
lack of control over data. However, secondary data used in this study were gathered,
curated, and validated by the government with the technical support of WHO. These
procedures were to ensure the accuracy of surveillance data and therefore raise internal
validity and specificity. The use of negative binomial regression model as statistical
analysis test in this research will contribute to reducing confounding. Countries and
WHO monitor the high quality by using meningitis case definition, deaths related to
meningitis, and the CSF samples laboratory testing to reduce selection bias. Few
selection biases might be found in some health districts (health facilities and
laboratories). It would have been valuable to determine the relationship between the
effects of MenAfriVac® and the other risk factors such as gender and age. Sequelae
would have also been valuable to found before and after MenAfriVac® introduction.
Unfortunately, gender, age, and sequelae were removed as variables because they were
not gathered by meningitis enhanced surveillance WHO IST WA database.
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Significance
This research filled the gap in the literature on the effectiveness of the
introduction of MenAfriVac® in the African meningitis belt, taking in consideration more
countries and period than the previous studies have done. Only one multi-country study
to estimate the effects of MenAfriVac® was conducted by Trotter et al. (2017) in nine
countries between 2010 and 2015. This multi-country study chose 21 countries and seven
years after since the introduction of MenAfriVac®. Few studies were conducted using
either carriage method or antibodies determination. These studies showed the early
effects of MenAfriVac® (Kristiansen, 2013; Novak et al., 2012; Diomandé et al., 2015;
Lingani et al., 2015; Collard et al., 2013; Djingarey et al., 2012, Djingarey et al., 2015).
The use of the surveillance is valuable because is a routine intervention that is conducted
in all countries, and it is useful and cost-effectiveness to monitor the trends of diseases
concerned, to detect epidemics, to evaluate the effectiveness of epidemic response, case
management, and effects of vaccination. The previous studies provided early effects in
few countries, and it was useful to conduct a research that included more countries and
many years after the beginning of the introduction of MenAfriVac®. This study could
also create positive social change in practice by fostering the countries to reinforce public
health policies in surveillance and immunization because of achievements obtained with
high MenAfriVac® immunization coverage and high quality of meningitis enhanced
surveillance.
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Summary
Meningococcal meningitis is a public health problem in Sub-Saharan Africa. Out
of the 12 meningococcal serogroups, N. meningitidis A represented for an estimated 80–
85% of meningitis disease before the introduction of MenAfriVac® in 2010 and since
2013, findings from the literature are showing that its proportion is being reduced. To
reduce the burden of Meningococcal meningitis caused by N. meningitidis A, a new
meningococcal conjugate A vaccine called MenAfriVac® was introduced in African
meningitis belt. The early effects of the introduction of MenAfriVac® in some countries
of meningitis belt showed the reduction of the incidence of N. meningitidis A. The
research purpose of this study was to assess the effectiveness of the introduction of a new
meningococcal conjugate A vaccine called “MenAfriVac®” in 21 countries of the
meningitis belt from 2010 to 2017, using the data of meningitis surveillance from 2004 to
2017 as a method of measurement. The socio ecological model was used to respond to
the research questions. The study was quasi-experimental research, interrupted time
series quantitative research design. This research filled the gap in the literature on the
effectiveness of the introduction of MenAfriVac® in the African meningitis belt, taking in
consideration more countries and period than the previous studies have done.
Chapter 1 provides a brief overview of the study’s purpose in the examination of
the effects of MenAfriVac® introduction in the African meningitis belt, 2010-2017.
Chapter 2 reviewed the literature delineating the effects introduction of MenAfriVac® in
African meningitis belt. Chapter 3 shows the details of the research methodology used in
the study.
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Chapter 2: Literature Review
Introduction
Meningitis disease remains a public health problem in the 26 high-risk countries
situated in the African meningitis belt. Before 2010, N. meningitidis A represented the
predominant meningitis pathogen and for an estimated 80% to 85% of meningitis
epidemics in Africa. Following the deadliest meningitis epidemics in 1996-97,
MenAfriVac® was developed. MenAfriVac® provided people who were vaccinated
individual protection and reduced the carriage of N. meningitidis A and, therefore,
increased the herd immunity (WHO, 2015a). According to WHO (2017, March 13), by
2016, 260.6 million people aged 1-29 years old were vaccinated with MenAfriVac®
through preventive campaigns in 19 countries. The 19 countries concerned were Benin,
Burkina Faso, Cameroon, Chad, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia,
Gambia, Ghana, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Nigeria, Senegal,
South Sudan, Sudan, and Togo. The research purpose of this quasi-experimental and
quantitative study was to assess the effectiveness of the introduction of a new
meningococcal conjugate A vaccine called MenAfriVac® in 21 out of 26 countries of the
meningitis belt from 2010 to 2017.
The major preview sections of this chapter are search literature strategy,
theoretical framework, a literature review related to key variables and concepts,
summary, and conclusion.
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Literature Search Strategy
There are 109 references found in following library database and search engines:
Walden University library, National Center Biotechnology Information, U.S. National
Library of Medicine–National Institute of Health (PubMed), Elsevier, WHO Library
Cataloguing, Programme for Appropriate Technology Health (PATH) Vaccine Resources
Library, Oxford University Press, University of Oslo Library, Princeton University, John
Libbey Eurotext, Google Scholar, Medline Plus, Medline, Semantic Scholar, and
Scientific Research Publishing, Inc., WHO websites, CDC Website, and PATH website.
Key search terms and combinations of search terms were meningitis, Africa,
carriage, Burkina Faso, Mali, Niger, MenAfriVac®, meningococcal meningitis,
meningitis belt, Neisseria meningitidis, Neisseria meningitidis serogroup A, PsA-TT,
Rollout of the group A meningococcal vaccine, new meningococcal vaccine, meningitis
epidemic, impact, conjugate vaccine, meningococcal A conjugate vaccine, surveillance,
serogroup A meningococci, and cerebrospinal meningitis. As stated above, there were
107 references found including 71 periodical peer-reviewed articles in 31 periodical peerreviewed journals, ten periodical newspaper articles, 17 articles in health agency
websites, 16 books, two meeting/conference and conference reports, and one meeting
press release. These references were published between 1963 and 2018, mainly in the 26
countries of African meningitis belt. Fifty-nine references were published within five
years from 2014 to 2018.
Currently, few studies have been conducted to determine the level and the
duration of immunogenicity of MenAfriVac®. The main purpose of these studies was to
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assess the duration of the persistence of antibodies against N. meningitidis A at a high
level among people vaccinated to provide effective protection. These studies were
conducted by WHO, CDC, AMP, PATH, and the National Institute of Public Health of
Oslo.
Theoretical Foundation
I used the SEM as a theoretical framework. Prevention refers to the efforts of
society to promote, protect, and sustain the health of the population. Vaccination is one of
the methods of prevention against vaccine-preventable diseases such as meningitis,
poliomyelitis, measles, rubella, and so forth. Vaccination aims to limit the incidence of
disease by protecting the population from attack before being affected. The SEM is a
theoretical framework for prevention. Therefore, SEM can be used to better understand
the effect of potential prevention strategies such as vaccination. Since 1979, the
ecological model and Bronfenbrenner’s ecological systems theory were developed by few
researchers. Following this, McLeroy, Bibeau, Steckler, and Glanz (1988) developed the
SEM of health promotion (CDC, 2015b; Glanz, Rimer, & Viswanath, 2008; Nyambe,
Van Hal, & Kampen, 2016).
According to McLeroy et al. (1988), SEM addresses the importance of
interventions directed at changing the individual, interpersonal, organizational,
community, and public policy factors that support and maintain unhealthy behaviors. The
model assumes that appropriate changes in the social environment will produce changes
in individuals and that the support of individuals in the population is essential for
implementing environmental changes. (CDC, 2015b; Elder et al., 1999; Glanz et al.,
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2008; McLeroy et al., 1988; Nyambe et al. 2016). The use of SEM helped to respond to
the four RQs selected. The four questions took into consideration the five approaches of
SEM to assess the effects of MenAfriVac®introduction in African maningitis belt
countries.
At the individual level, biological and personal history factors that increase the
likelihood of becoming affected by meningococcal meningitis serogroup A were
identified. The purpose was to increase the individual’s knowledge and influence
attitudes, behavior change, and beliefs. At the second level, the interpersonal, close
relationships that may increase the risk of becoming affected by meningococcal
meningitis serogroup A were examined. This level was intended to facilitate individual
behavior change through a social network or social support systems by affecting social
and cultural norms and overcoming individual-level barriers. The third level of the SEM
was the community. In this research I explored the settings of overcrowding that is one of
the risk factors of meningococcal meningitis serogroup A. These settings might be
schools, markets, workplaces, households, and neighborhoods. Activities might be
developed and implemented to provide individual and community behavior changes. The
involvement and the participation of individuals, communities, and institutions could
contribute to promoting elimination of meningococcal meningitis serogroup A in Africa.
The fourth level was organizational. It represented prevention activities implemented at
the organization level. These activities were intended to facilitate individual behavior
change by influencing organizational systems. The fifth level was societal or policy level.
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In this level, activities involved interpreting and implementing existing policy that might
promote healthy behavior that contributed to eradicating meningococcal meningitis A.
The SEM Has been applied to vaccination and the assessment of new vaccines.
For example, Kumar et al., (2012) conducted a study that examined influenza vaccine
uptake during the 2009 H1N1 pandemic in the United States. The use of SEM was
largely focused on individual determinants (perceived risk, past vaccine acceptance,
perceived vaccine safety) and physician recommendation. Nyambe et al. (2016) found
that SEM as the multilevel model was effective for vaccination for controlling the spread
of a vast number of diseases and conditions. The United Nations Children's Fund
(UNICEF) has used SEM in this manner to support countries in improving their public
health policies that require childhood immunizations (CDC, 2015b).
I chose this theory because all five approaches fit with the topic of the
dissertation. SEM is based on evidence that no single factor can explain why some people
or groups are at higher risk for meningococcal meningitis while others are more protected
from it. This framework viewed protection with MenAfriVac® as the outcome of
interaction among many factors. These factors were the individual, the interpersonal, the
community, organizational, and the societal levels. The societal level was characterized
by the quality of the public health policy used to organize immunization campaigns and
routine programs with the involvement of the health institution and researchers to
contribute to eliminating meningococcal meningitis due to N .meningitidis A.
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Literature Review
Meningococcal Meningitis: Overview
Definition and pathogens. Meningitis is an infection of the membranes covering
the brain and spinal cord. Meningococcal meningitis is the common form of meningitis
infection. It can be defined as a bacterial form of meningitis caused by N. meningitidis. It
is an infection of the thin lining that surrounds the brain and spinal cord that can cause
severe brain damage. It is very serious and can be deadly: it is fatal in 50% of cases if
untreated, and almost 20% of survivors suffer serious sequelae such as deafness and
mental retardation (CDC, 2014; WHO, 2015a, WHO, 2015b, National Institute of Health,
2016; Agauado et al. (2015); Kiefer, 2016). Of the 13 serogroups of N. meningitidis
identified, four (N. meningitidis. A, B, C, and W135) are recognized to be the main
causes of epidemics, while occasional outbreaks are also caused by N. meningitidis X and
Y. Meningococcal meningitis cases occur throughout the world. Large, recurring
epidemics affect the meningitis belt. Before 2010, N. meningitidis A was responsible for
the large majority of epidemics in this area. In this area, outbreaks occur during the dry
season, usually covering a period between January and June (WHO, 2015a; WHO 2015b;
WHO, 2017 March 13).
Risk factors. The common risk factors are being 1 to 29 years old, community
setting, and travel. Travelers may be at increased risk particularly during the dry season
(December to June) and in Mecca during the annual Hajj and Umrah pilgrimage. A
relationship between the environment and the location of meningococcal meningitis
epidemics has been found. The findings show that meningococcal meningitis has the

27
greatest incidence for large epidemics in Africa in the dry season. The dry season
coincides with periods of very low humidity and dusty conditions and disappears with the
onset of the rains, suggesting that these environmental factors may also play an important
role in the occurrence (CDC, 2014; Greenwood, 1999; Lapeyssonnie, 1963; Molesworth
et al., 2003)
Transmission, symptoms, and complications. N. meningitidis is transmitted
from person-to-person through droplets of respiratory or throat secretions from carriers.
Ten percent to 20% of the population carries N. meningitidis in their throat at any given
time, and this carriage rate may be higher in epidemic situations. The average incubation
period is 4 days but can range between 2 and 10 days. N. meningitidis only infects
humans (WHO, 2014b, WHO, 2015b). The most common symptoms of meningitis
disease are a headache, stiff neck, confusion, vomiting, sensitivity to light, high fever,
skin rash, and convulsions. The common complications are septicemia, endocarditis,
arthritis, and sequelae such as partial or total hearing loss, memory and concentration
problems, partial or total vision loss, insomnia, speech problems, migraine, and epilepsy
(Kiefer, 2016; WHO, 2014b; WHO, 2015b).
Diagnosis. The diagnosis of meningococcal meningitis can be made by clinical
examination followed by a lumbar puncture showing a purulent spinal fluid. The bacteria
can sometimes be seen in microscopic examinations of the spinal fluid. The diagnosis is
supported or confirmed by growing the bacteria from specimens of spinal fluid or blood,
by agglutination tests or by PCR. The identification of the serogroups and susceptibility
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testing to antibiotics are important to define control measures (WHO, 2009a; WHO,
2009b; WHO, 2014c; WHO, 2015a)
Pillar strategies for elimination of meningitis in Africa. The three pillar
strategies for elimination of meningitis in Africa are as follows: surveillance, treatment
and care, and vaccination (WHO, 2015b, WHO, 2015, February 20; WHO, 2015,
November 20). Enhanced meningitis surveillance has been implemented since 2002 in
countries of the African meningitis belt. The main objectives are to rapidly collect,
disseminate, and use weekly district data on meningitis incidence. Standard operating
procedures for meningitis enhanced surveillance were developed to guide countries.
Concerning treatment and care, even when the meningitis is diagnosed early and
adequate treatment is started, 5%-10% of patients die, often 24 to 48 hours after the onset
of symptoms. Few antibiotics can treat meningitis infection. Ceftriaxone by injection is
recommended as the first treatment for a minimum of 5 days (WHO, 2014b; WHO,
2014c; WHO, 2015b). Concerning the vaccination pillar strategy, it contributes to reduce
the incidence of meningitis disease (preventive vaccination) and to limit the magnitude of
the epidemic (reactive vaccination). There are polysaccharide and conjugate monovalent
and polyvalent vaccines available that are used both for preventive and reactive
immunization, vaccines against Streptococcus pneumoniae and Haemophilus influenzae
as well (WHO, 2011 November; WHO, 2014b; WHO, 2014c; WHO, 2015a; WHO,
2015b; WHO, 2017 March 13). The main objectives of surveillance are to evaluate the
impact of vaccination, to detect and investigate epidemics and to provide material for
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research (Djingarey et al., 2008; Harrison et al., 2009; Lingani et al., 2015; Mueller,
2013; WHO, 2015; WHO & CDC, 2010).
Epidemiology of Meningococcal Meningitis
Meningococcal disease is a leading cause of bacterial meningitis and sepsis, and a
major cause of epidemics in sub-Saharan Africa. The causative organism is Neisseria
meningitidis. Meningococcal meningitis is a major public health problem and burden
worldwide especially in the extended meningitis belt of sub-Saharan Africa. The
extended meningitis belt stretching from Senegal in the west to Ethiopia in the east where
an estimated 450 million people are at risk from meningitis epidemics are living. 26
countries at highest rates of the disease are in meningitis belt (WHO, 2015a; CDC,
2015a; PATH, 2016a; Nicolas, 2012). Before 2010 and the mass preventive
immunization campaigns, N. meningitidis A accounted for an estimated 80–85% of all
cases in the meningitis belt, with epidemics occurring at intervals of 7–14 years.
Manigart et al. (2016) showed that before vaccination with the serogroup A
meningococcal conjugate vaccine, meningococcal serogroup A IgG antibody
concentrations were high across the African meningitis belt and yet the region remained
susceptible to epidemics. The human and socioeconomic toll of these epidemics is
devastating. By far the highest incidence of meningococcal disease occurs in the
meningitis belt of sub-Saharan Africa. During epidemics, the incidence can approach
1000 per 100,000, or 1% of the population (CDC, 2015a; Harrison et al., 2009).
Some countries of meningitis belt reported deadly epidemics due to N.
meningitidis A. The largest meningococcal meningitis. An epidemic was reported in 1996
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and 1997 with more than 25,000 people died and more than 250,000 were sickened. In
2009 more than 88,000 people in Africa were stricken by meningitis (Nicolas, 2012;
PATH, 2016a; Vergnano & Health, 2003). Caugant et al. (2012) found that in the seven
years preceding the introduction of a new serogroup A conjugate vaccine, serogroup A of
the ST-5 clonal complex was identified as the predominant disease-causing strain. Sow et
al. (2011) stated that N. meningitidis A was the source of major epidemics of meningitis
in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine was
needed. Thus, since 2010, some authors found that the proportion of N. meningitidis A
has declined significantly. The bacterial profile has changed with the predominance of, N.
meningitidis W135, N. meningitidis C, N. meningitis X, S. pneumoniae (Collard et al.,
2013; Trotter et al., 2017; Retchless et al., 2016; Carod, 2015; WHO, 2017, March 13).
MenAfriVac® Vaccine
Public health initiative and Meningitis Vaccine Project (MVP). Following the
devastating epidemic of 1996–97 African leaders called for the development of an
affordable vaccine less than US$ 0.50 that would eliminate, once and for all, group A
meningitis epidemics in Africa (PATH, 2016b; Aguado et al., 2015; Tiffany et al., 2015).
WHO accepted the challenge and created a project called Epidemic Meningitis Vaccines
for Africa (EVA) that served as an organizational framework for external consultants,
PATH, CDC and Bill and Melinda Gates Foundation (BMGF) (WHO 2011; WHO
2014b; Aguado et al., 2015). In June 2001, BMGF awarded a grant of US$ 70 million to
create the MVP as a partnership between PATH and WHO. The specific goal of MVP
was the development, licensure, and the introduction of MenAfriVac® in meningitis belt
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countries to eliminate meningitis A epidemics in Africa (Okwo-Bele et al., 2015; PATH,
2016b; Aguado et al., 2015; Idoko et al., 2014 ; Frasch et al., 2012; WHO, 2010,
December 6).
Development of PsA-TT (MenAfriVac®) and ethical challenges. WHO (2015,
February 20), Frasch et al. (2012), and Idoko et al. (2014) showed that an affordable
monovalent MenA polysaccharide-tetanus toxoid conjugate vaccine (MACV/ PsA-TT)
so-called MenAfriVac® was developed. This vaccine is against meningococcal
meningitis caused by N. meningitidis A. This vaccine was developed by scientists
working with MVP. A high-efficiency conjugation method was developed in the
laboratory of bacterial polysaccharides in the center for biologics evaluation and research
and transferred to the Serum Institute of India, Ltd (SILL). Then after, SILL developed
methods of purification of group A polysaccharide and used tetanus toxoid as the carrier
protein to produce the new licensed, highly effective MenAfriVac® conjugate vaccine.
The PsA-TT conjugate vaccine is a lyophilized preparation that is reconstituted before
injection. The vaccine is administrated intramuscularly (Frasch et al., 2012). A 5µg
formulation was prequalified by WHO for routine immunization while 10µg formulation
was prequalified for vaccination mass campaign.
Ethical issues encountered during clinical trials of PsA-TT and they have been
rose and were well-taken in consideration. Martellet et al. (2015) showed that groups that
conducted the clinical trials successfully resolved ethical issues that arose. The key
factors of the success in all the sites of clinical trials were the constant dialogue between
partners to explore and answer all ethical questions. Also, the alertness and preparedness
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for emerging ethical questions during the research and the context of evolving
international ethics standards were followed. The care to assure that approaches were
acceptable in the diverse community contexts was effective.
Idoko et al. (2015) and Berlier et al. (2015) emphasized the relevant role played
by the communications strategy that engaged stakeholders, potential supporters, and
communities concerned during the development of PsA-TT. Moreover, Idoko et al.
(2015) stated that the understanding and integration of sociocultural realities of
communities were major assets in the conduct and acceptance of these trials in Gambia,
Ghana, and Senegal. Communication, rumor management, recruitment, sharing results
with communities involved and the consent were relevant and well-prepared and wellconducted. Therefore MVP succeeded in these sites and provided a sound example for
future clinical studies in Africa. Okwo-Bele et al. (2015) and PATH (2016c) emphasized
the successful partnership between WHO and PATH, an international nonprofit
organization during the development, and licensure of PsA-TT. The development,
licensure of MenAfriVac® a safe, effective and affordable vaccine to face a dramatic
public health problem in Africa was a relevant public-private partnership. Therefore, it
had shown the possibility and challenge to develop other vaccines especially targeting
populations in developing countries (Tiffany et al., 2015; Okwo-Bele et al. (2015);
PATH, 2016c, Bishai et al., 2011, Jódar et al., 2003).
Immunogenicity, safety, licensure, prequalification, and registration of
MenAfriVac®. Sow et al. (2011), Frasch et al. (2015), Tapia et al. (2015), WHO (2015,
February 20), and Idoko et al. (2014) demonstrated that PsA-TT 10 µg and 5 µg when
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tested in Africans between 1 and 29 years of age had a safety profile, well-tolerated, and
more persistent response from functional antibodies against N. meningitidis A. They also
found that PsA-TT could induce immunologic memory and induced herd immunity. All
participants had a significant response to antibody titers especially after receiving PsATT. Therefore, the introduction of PsA-TT could potentially decrease epidemics caused
by N. meningitidis A in the African meningitis belt. In another hand, WHO (2014b),
WHO (2014d), and Karachialou et al. (2015) showed that MenAfriVac® introduction
trough vaccination mass campaigns must be completed by the introduction in routine
immunization program for children between 9 to 18 months. That will contribute to a
sustainable elimination of meningococcal meningitis A. an additional benefit of
immunizing with PsA-TT is the carrier protein tetanus toxoid (TT) itself. PsA-TT has
been shown to generate effective tetanus protection (Borrow et al., 2015).
Concerning the pharmacovigilance activities during the development of PsA-TT
and the implementation of vaccination mass campaigns, Diomandé, Yaméogo,Vannice et
al. (2015), Wak et al. (2015), and Vannice et al. (2015) enlighted the relevance of
monitoring and review serious adverse events following immunization (AEFIs) in all
countries. These activities are being conducted by the national expert advisory groups in
all countries that introduced MenAfriVac®. As during the clinical trials, AEFIs reported
were not significant during the vaccination mass campaigns showing that MenAfriVac®
is safe for people vaccinated including pregnant women (WHO, 2006; Diomandé,
Yaméogo, Vannice, et al., 2015; Wak et al., 2015; Vannice et al., 2015). The vaccine was
successfully tested in Phase I, II and II/III clinical trials in India and African countries of
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the meningitis belt that are Mali, The Gambia, and Senegal. In December 2009,
MenAfriVac® 10µg was licensed in India for vaccination of individuals 1-29 years old in
Africa. It was prequalified by WHO in June 2010 for vaccination mass campaigns. In
October 2014, MenAfriVac® 5µg was prequalified by WHO for children aged 3-23
months. All the 21 countries that introduced MenAfriVac between 2010 and 2017
registered at national level the PsA-TT prior the vaccination mass campaign and
introduction into routine vaccination programme (WHO, 2011; PATH, 2014; WHO,
2014b; WHO, 2014d; WHO, 2015 January 9, Frasch et al., 2012; Novak et al., 2012).
MenAfriVac® is affordable costing less than US$ 0.50 per dose (Sambo et al.,
2015). Laforce et al. (2011) found that MenAfriVac® is expected to be cost-saving when
compared to expenditures epidemics caused by N. meningitidis A. On the same line,
Colombini et al. (2011) stated that MenAfriVac® should contribute to the more efficient
use of funds dedicated to meningitis epidemics and limit the disruption of routine health
services. Socioeconomic impact study estimated the expected health outcomes, treatment
costs, vaccination costs, and cost-effectiveness of vaccination in the hyper endemic
countries over a six-year-period (PATH, 2016d)
MenAfriVac® Rollout in Africa
Only the health districts that are at highest risk are selected to introduce
MenAfriVac®. The selection is made through the risk assessment using the district
prioritization tool developed by WHO (Cibrelus et al., 2015). After the selection of health
districts in each country, the next step is to apply to GAVI alliance for a grant that will
help to finance vaccine costs and operational costs for the preparation, implementation,
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monitoring, and evaluation of the vaccination mass campaign. All the 21 countries
selected for this study have followed all the steps of the process shown above. The herd
protection and individual protection become while health district has obtained at least
90% of administrative coverage or 70% of immunization coverage from the independent
coverage survey. Therefore, one of the objectives of the vaccination mass campaign is for
each health district to reach at least 90% of administrative coverage. The findings in the
literature show that the preparation, implementation, monitoring, and evaluation have
been well-done in the 21 countries involved in this research. Some authors found that the
majority of communities living in highest risk health districts were engaged and
participated effectively in preparation, implementation, and evaluation of vaccination
mass campaigns, public health professionals, researchers, community and political
leaders as well. Djingarey et al. (2012) showed that African national immunization
programs are capable of achieving very high coverage for a vaccine desired by the public,
introduced in a well-organized campaign, and supported at the highest political level. In
Burkina Faso, the ensuing 10-day national campaign was hugely successful, and 100% of
target population aged between 1 and 29 years were vaccinated. In the same line,
Djingarey et al. (2015) found that between 2010 and 2014 the preparation and
implementation of vaccination mass campaigns were relevant and the participation of
communities concerned exemplary. Few studies conducted by PATH (2016a), Idoko et
al. (2015), Martellet et al. (2015), Belier et al. (2015), and Okwo - Bele et al. (2015)
provided information on the contribution of social values while introducing
MenAfriVac®. These social values were the community engagement, the government
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commitment, and the accountability of public health agencies and researchers reported to
achieve the goal of the elimination of meningitis disease due to N. meningitidis A in
Africa.
Djingarey et al. (2015) found that from 2010 to 2014, 217 million persons aged 129 years were vaccinated in 15 out of 26 countries of meningitis belt with the country
coverage rates ranging from 85% to 95%. WHO (2017, March 13) showed that from
2010 to 2016, 260.6 million persons in 19 countries aged from nine months to 29 years
old were vaccinated with MenAfriVac®. In 2017, two additional countries Uganda and
Central African Republic (CAR) have introduced MenAfriVac® respectively in January
and March-May.
Early Effects of the Introduction of MenAfriVac®
Since 2010, the serogroup A conjugate vaccine (MenAfriVac®) is being
introduced through mass campaigns and routine immunization to countries of the
meningitis belt. Between 2010 and 2016, 260.6 million persons aged between nine
months to 29 years were vaccinated in 19 countries (WHO, 2017 March 13). The age
group concerned by vaccination mass campaigns is 1 -29 years with MenAfriVac® 10µg.
Whereas the age group concerned by routine immunization program varies between nine
to 18 months with MenAfriVac® 5µg (WHO, 2014d; WHO, 2017a; WHO, 2011
November; who, 2015 February 2). According to WHO (2014d) and WHO (2015,
February 20), both immunization through the mass campaign and routine program are
critical for a sustainable elimination of N. meningitidis A. Obaro and Habib (2016) stated
that after the widespread vaccination with serogroup A conjugate vaccine of people aged
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1–29 years from 2011 to 2014, the susceptible pool of unvaccinated people has increased
because routine vaccination has not been introduced.
The early effects are being found by some authors. The global reduction of the
incidence and occurrence of meningitis epidemics caused by N. meningitidis A in the
meningitis belt were shown by WHO (2014d), WHO (2015b), WHO (2016b), WHO
(2017), PATH (2016d), PATH and WHO (2016), WHO (2017, October 13), and Dakar
discussion group on priorities for research on epidemic meningococcal disease in Africa
et al. (2013). Some authors assessed the effects of MenAfriVac® within one or few
countries between 2012 and 2016 using as measurement instrument carriage study or
antibodies determination or surveillance. Surveillance is used in this study to assess the
effects of MenAfriVac®. The other authors who found the effective impact of
MenAfriVac®, using surveillance are Novak et al. (2012) and Diallo et al. (2017) in
Burkina Faso. Maïnassara et al. (2015) found the predominance of N. meningitidis C
epidemics after the introduction of MenAfriVac® in 2010 in Niger. Lingani et al. (2015)
found that confirmed a dramatic fall in N. meningitidis A incidence after the introduction
of MenAfriVac® between 2004 and 2013 within ten countries (Benin, Burkina Faso,
Chad, Democratic Republic of Congo, Ghana, Côte d'Ivoire, Mali, Niger, Nigeria, and
Togo). Trotter et al. (2017) found in nine countries (nine countries- Benin, Burkina Faso,
Chad, Côte d’Ivoire, Ghana, Mali, Niger, Nigeria, and Togo) the reduction of the
incidence and epidemics in epidemics due to N. meningitidis A after the introduction of
MenAfriVac®. Diallo et al. (2016) reported the first documented MenAfriVac® vaccine
failure in Burkina Faso in 2015.
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Kristiansen (2012) and Kristiansen et al. (2013) found the effectiveness of
MenAfriVac® on the carriage of N. meningitidis A among persons vaccinated in Burkina
Faso. The similar result with the carriage measurement was found by Daugla et al. (2013)
in Chad. Using the culture, seroagglutination and speciation PCR, followed by
genogrouping PCR for N. meningitidis, Collard et al. (2013) found the reduction of
incidence of N. meningitidis A and the predominance of N. meningitidis W135 in Niger
from 2008 to 2011. The similar findings were showed by Retchless et al. (2016) in
Burkina Faso and Mali. Carod (2015) found that the predominant of non-N. Meningitidis
A after the introduction of MenAfriVac® in African meningitis belt.
The population-level persistence of immunity few years after the MenAfriVac®
mass vaccination campaigns in few countries have been found. Basta et al. (2015) found
in Mali the persistence of immunity two years after the campaign. Diomandé, Djingarey,
Daugla, et al. (2015) found the persistence of immunity four years after the campaigns in
Burkina Faso and Chad. MenAfriCar consortium (2016) found that Meningococcal
serogroup A IgG antibodies by country and by sub-group were high in the populations of
six countries (Ethiopia, Senegal, Mali, Ghana, Mali, Nigeria) investigated.
Kristiansen et al. (2015), found that the administration in mass vaccination
campaigns of a single dose of MenAfriVac®, to the target (1-29 years old) population of
sub-Saharan Africa has prevented epidemics of meningitis caused by serogroup A
Neisseria meningitidis. This strategy has also been shown to provide herd protection of
the non-vaccinated population. Moreover, WHO and PATH (2016, February) declared
during the closure MVP meeting that meningitis A is nearly eliminated in Africa through
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vaccination. In the same line, Sambo et al. (2015) stated that MenAfriVac® met its
promise and the success in controlling epidemic meningococcal meningitis in SubSaharan Africa is noted.
Summary and Conclusions
The literature review shows that meningococcal meningitis remains a major
public health problem worldwide and Africa the most affected. N. meningitidis A before
the introduction of MenAfriVac® accounted for 80-85% of meningitis cases and
epidemics. Following the devastating epidemic of 1996–97 African leaders called for the
development of an affordable vaccine that would eliminate, once and for all, N.
meningitidis A meningitis epidemics in Africa. The collaboration of WHO, PATH, and
SIIL contributed to developing and to licensure MenAfriVac® with a grant provided by
BMGF. MenAfriVac® has effective immunogenicity. This vaccine is safe and was
prequalified by WHO in 2009 for vaccination mass campaigns among people aged 1-29
years and in 2014 among children aged 9-18 months old. MVP with the partnership of
public health professionals, communities, and governments support the preparation and
implementation of vaccination mass campaigns with MenAfriVac® and its introduction
into routine immunization programs in the meningitis belt. Almost 280 million people
have been vaccinated in 21 out of 26 countries of meningitis belt from 2010 to June 2017.
The early effects of the introduction of MenAfriVac® show the reduction of incidence of
N. meningitidis A and the occurrence of epidemics due to N. meningitidis A.
The purpose of this study was to fill the gap in the literature by assessing the
effects of MenAfriVac® in more countries and several years after the introduction in
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2010 than the previous studies. This study also helped to provide more information on the
relationship between MenAfriVac® introduction and the CFR, and the strength of the
relationship between MenAfriVac® introduction and N. meningitidis A. Another gap to
fill was to establish the relationship between the introduction of MenAfriVac® and the
occurrence of epidemics caused by N. meningitidis A. while showing in this study the
advantage of having high MenAfriVac® immunization coverage and performant
meningitis surveillance, it will create a positive social change fostering the improvement
of public health policies.
The background showed the definition of meningococcal meningitis, the
pathogens, risk factors, symptoms, complications, and diagnosis. The second part of the
literature was marked by how the initiative to eliminate meningitis An epidemic as a
public health problem in Africa, the development, immunogenicity, licensure, safety, and
prequalification of MenAfriVac®. Then, the third part showed the MenAfriVac® roll-out
and, the last part provided the early effects of MenAfriVac®. The next chapter presents
the research design and rationale and the methodology. The methodology presents the
population, sampling and sampling procedures, procedures for recruitment participants,
and data collection, instrumentation and operationalization of instruments, research
questions, variables, the operationalization of data analysis plan, threats of validity, and
ethical procedures.
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Chapter 3: Research Method
Introduction
The research purpose of this study was to assess the effectiveness of the
introduction of a new meningococcal conjugate A vaccine called MenAfriVac® in 21 out
of 26 countries of the meningitis belt in Africa from 2010 to 2017. The major sections of
this chapter are the introduction, research design and rationale, and methodology
(population, sampling and sampling procedures, procedures for recruitment participants,
data collection, instrumentation and operationalization of instruments, research questions,
variables, and the operationalization of data analysis plan), threats of validity, and ethical
procedures.
Research Design and Rationale
I chose four dependent variables and one independent variable to achieve the
purpose of this study. The dependent variables selected were the occurrence of N.
meningitidis A or not (another pathogen than N. meningitidis A, negative CSF sample),
incidence rate of meningitis suspected cases, CFR, deaths, and occurrence of meningitis
epidemics. The independent variable was MenAfriVac® vaccination status of the health
district (vaccinated after the introduction of MenAfriVac®; vaccinated with any another
polysaccharide vaccine that includes antigen A; unvaccinated before the introduction of
MenAfriVac®). Pathogens were isolated from CSF samples by culture or detected by
latex agglutination test or PCR.
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The study was quasi-experimental, retrospective, and quantitative. It was also
consistent with the research design chosen. The research design was an interrupted time
series. Secondary data retrieved from WHO IST WA database concerned meningitis
suspected cases, CFR, deaths, N. meningitidis A confirmed cases, and occurrence of
epidemics due to N. meningitidis A before and after 2010. Secondary data from
meningitis enhanced surveillance and MenAfriVac® coverage concerned the period from
2004 to 2017. No time and resource constraints were found.
Methodology
Population
The population of this study was characterized by people living in 1,713 out of
3,817 health districts at highest risk for meningitis in 21 countries of the African
meningitis belt. Health districts at highest risk for meningitis were selected to introduce
MenAfriVac®. The selection was made through risk assessment using the district
prioritization tool developed by WHO (Cibrelus et al., 2015). The 21 countries that were
participants of this study were Mali, Burkina Faso, Cameroon, Central Africa Republic,
Chad, Benin, Cote d’Ivoire, Togo, Mauritania, Niger, Nigeria, Ghana, Gambia, Guinea,
Guinea Bissau, Ethiopia, Sudan, South Sudan, Senegal, and Uganda. The total estimated
population was 407,958,506 persons. People who were vaccinated with MenAfriVac®
were aged 1-29 years old because they were the highest risk of meningitis infection
caused by N. meningitidis A. The age group 1-29 years old represented almost 70% of the
total population. The estimated target population for MenAfriVac® vaccination was
285,570,957 people. Figure 1 and Table 1 show that between 2010 and 2017,
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286,995,073 were immunized with MenAfriVac®, thus there was 100% administrative
coverage in the 21 countries of the study. The target population of this study was large
and representative. The findings can be generalized.

Figure 1. African Meningitis Belt and MenAfriVac® Roll-out 2010-17. (Source WHO).
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Table 1
People Vaccinated With MenAfriVac® 2010-17
Health districts
at high risk
covered
By
MenAfriVac
vaccination
campaign

3708077

Total
population
2017 at
meningitis
risk

Countries

Benin
Burkina Faso

Years of
introduction

The target
population for
MenAfriVac
vaccination
campaigns

Persons
vaccinated

Administrative
coverage

33

2013

2595654

2718459

105%

21557784

63

2010, 2016

15090449

15295276

101.35%

Cameroon

8751220

70

2011-12

6125854

6510729

112.80%

Central African Republic

5226069

30

2017

3658248

3220358

88.24%

13177019

99

2011-12

9223913

8732151

95

3244287

42

2014

2271001

2764839

100.40%

Democratic Republic of Congo

26008263

149

2016

18205784

18058535

99.20%

Ethiopia

88330603

102

2013-15

61831422

60996186

98.64%

Gambia

1682750

7

2013

1177925

1228419

104%

Ghana

5395356

49

2012, 2016

3776749

3705081

98.10%

Guinea

3657747

15

2015

2560423

2442566

95.40%

Guinea Bissau

1821931

11

1275352

1150136

90.10%

20260730

60

14182511

14593475

102.89%

2300747

33

2016
2010, 2011
2016
2014

1610523

1561720

97%

Chad
Cote d’Ivoire

Mali
Mauritania
Niger

15529739

42

2010

10870817

10575365

95.70%

Nigeria

118680713

571

2011-14

83076499

87062324

104.79%

Senegal

6261793

35

2012

4383255

4216691

96.20%

South Sudan

6246709

47

2016

4372696

4023659

92%

42176594

188

2012-13

29523616

28232735

95.62%

Sudan
Togo
Uganda
Total

3934556

28

2014

2754189

2764839

102.20%

10005820

39

2017

7004074

7141530

102%

407958506

1713

2010-17

285570954

286995073

100.49%

Note. Source WHO.

Sampling and Sampling Procedures
Nonprobability sampling was chosen because all countries that introduced
MenAfriVac® between 2010 and 2017 were participants. I intended this choice to have
more evidence of the effects of MenAfriVac® that can be generalized. The countries
included in this study are located in the African meningitis belt, and they introduced
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MenAfriVac® between 2010 and June 2017. The other African countries are excluded.
This study took into consideration all CSF samples tested in the laboratory with either
culture, latex agglutination test, or PCR. CSF samples were transported from healthcare
facilities to the district or national reference laboratories, which conducted laboratory
testing. Cytology and gram staining found for probable meningitis were excluded in this
study. WHO recommended that any reported N. meningitidis A case after MenAfriVac®
introduction should be investigated.
I used the non-probably sampling method instead of random sampling to have
more evidence that could provide greater validity with generalization. The minimum
sample size was 144 calculated using G*Power 3.1.9.2. I used the following estimated
parameters to calculate the minimum sample size: confidence interval chosen was 95%
with Z =1.96, alpha = .05, type II error =20%, power = 80% with two tails. For this study,
the estimate sample size of CSF samples was over 100,000. The estimate of incidence
rate of meningitis suspected cases and deaths was over 400,000. Moreover, the number of
health districts that reported epidemics caused by N. meningitidis A from 2004 to June
2017 was over 200. With the large sample size, the results could be generalized with
appropriate size effect.
To measure effects of MenAfriVac® introduction in the African meningitis belt, I
retrieved data from meningitis enhanced surveillance between 2004 and 2017 and
MenAfriVac® immunization coverage from WHO ISTWA database. I found other
relevant information on meningitis enhanced surveillance and polysaccharides vaccines
immunization coverage in archives and meningitis bulletins posted in public WHO
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websites. A data use agreement to retrieve the data for this study was given by WHO
regional director of Africa in December 2017 following the request in December 2016.
The secondary data from meningitis enhanced surveillance concerned meningitis
suspected cases that fit the case definition, CFR, CSF samples tested in laboratories, and
the meningitis epidemics reported using meningitis epidemic threshold. Concerning
MenAfriVac® coverage provided by mass vaccination campaigns and routine
immunization programmes, they were retrieved from WHO ISTWA database. I also
found data from meningitis surveillance and MenAfriVac® coverage in the WHO IST
WA databases. These are aggregated data sent by countries on a weekly basis concerning
meningitis surveillance and monthly about routine immunization or by one month
following mass vaccination campaigns. These data were collected, treated, consolidated,
harmonized, and validated at the country level before they are sent to WHO ISTWA.
WHO and other partners such as CDC provide technical support to have accurate data at
each level of the health system. WHO and CDC have developed together reference
documents on standard operating procedures for meningitis surveillance; they also have
supported training in the African meningitis belt since 2002. Data quality audits and
supervision are being done to improve the quality of surveillance data from health
facilities directly to the central level (WHO, 2014c; WHO & CDC, 2010). These
procedures were developed to assure their accuracy. Data quality audits are being doing
at all levels by ministries of health with WHO to ensure the accuracy of data shared in the
health information system.
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Instrumentation and Operationalization of Constructs
The measuring instrument that I used in this study was enhanced surveillance.
Enhanced surveillance is the continuous, systematic collection, analysis, and
interpretation of health data linked with giving feedback to people at all levels of the data
collection chain. Enhanced surveillance serves as an early warning system for impending
public health emergencies. Surveillance also serves to evaluate and to document coverage
and effectiveness of programme interventions such as the introduction of new vaccines. It
also contributes to track progress towards specified goals and monitor the epidemiology
of health problems. Meningitis enhanced surveillance was developed in 2002 by WHO
and CDC to reinforce the meningitis surveillance (Johns Hopkins et al., 2008; MacNeil,
& Cohn, 2013; WHO, 2009a; WHO, 2014b; WHO, 2017b; WHO & CDC, 2010).
Enhanced surveillance is a relevant measure to evaluate the effects of the
introduction of a new vaccine such as MenAfriVac®. The goals of meningococcal
enhanced surveillance are: to detect outbreaks of meningococcal disease so that
appropriate control measures can be promptly instituted and to assess changes in the
epidemiology of meningococcal disease over time to permit the most efficient allocation
of resources and formulation of the most effective disease control and prevention
policies. Meningococcal serogroup surveillance data are important to monitor and assess
the impact of new vaccines. The African meningitis belt countries have national plans for
integrated disease surveillance and response, which include meningitis. WHO supports
those countries to strengthen their disease surveillance, especially meningitis surveillance
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(Djingarey et al., 2008; Harrison et al., 2009; MacNeil, & Cohn, 2013; Mueller, 2013;
WHO, 2009a, WHO, 2014a; WHO, 2015; WHO & CDC, 2010).
The two key concepts that determine the high quality of enhanced surveillance are
reliability and validity. The appropriateness or quality of surveillance information
depends on the accuracy of that information (Teutsch & Churchill, 2000). Enhanced
surveillance is relevant because it provides high validity and reliability. Data provided
must be accurate. Based on its reliability and validity, WHO recommends surveillance to
assess effects of the new vaccines. The purpose of meningococcal surveillance is to
detect epidemics of meningococcal disease, to assess changes in the epidemiology of
meningococcal disease over time, to build efficient prevention policies, and to monitor
and evaluate the impact of meningococcal vaccine (Djingarey et al., 2008; Harrison et al.,
2009; MacNeil, & Cohn, 2013; Mueller, 2013; WHO, 2009a, WHO, 2014a; WHO, 2015;
WHO & CDC, 2010; ). Studies conducted by Diallo et al. (2017), Djingarey et al. (2015),
Lingani et al. (2015), Novak et al. (2012), and Totter et al. (2017) showed effects of
MenAfriVac® using meningitis enhanced surveillance as measure instrument.
Data and information found in WHO IST WA databases were accurate based on
the procedures followed within countries with the technical support of WHO country
staffs that help to collect and to curate data before sending. The data from surveillance
were treated, harmonized, validated with the stakeholders of the surveillance system with
the technical support of partners such as WHO and CDC to assure their reliability and
validity. Meningitis surveillance implements within countries supported by WHO
presents timeliness, representation, sensitivity, and specificity. Meningitis surveillance is
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being strengthened with the technical support of WHO and CDC since 2002. Many
authors used surveillance as a measure of the instrument to evaluate the effectiveness of
vaccines. Novak (2012), Lingani et al. (2015), Djingarey et al. (2014), Diallo et al.
(2017), and Trotter et al. (2017) used meningitis surveillance to assess the early effects of
MenAfriVac® in Africa.
Meningitis enhanced surveillance helped to respond to the four research questions
of this study by providing incidence of meningitis suspected case definition, CFR, and
occurrence of meningitis epidemics between 2004 and June 2017. The definition and
characteristics of these key elements are as follows:
Case definition of meningitis disease: Any person with sudden onset of fever
(>38.5 °C rectal or 38.0 °C axillary) and neck stiffness or another meningeal sign
including bulging fontanel in toddlers (WHO, 2015b).
Suspected case (of meningitis): Any person with sudden onset of fever (>38.5oC
rectal or >38.0oC axillary) and one of the following signs: neck stiffness, flaccid neck,
bulging fontanelle, convulsion or other meningeal signs (WHO, 2014c).
Confirmed meningitis case: Any suspected or probable case that is laboratory
confirmed by culturing or identifying. Identification can be done either by PCR or
immunochromatographic dipstick or latex agglutination of pathogens in the CSF or blood
(WHO, 2015b).
Alert threshold: A level of incidence that triggers action to prepare for an
epidemic, including strengthening surveillance, confirming cases, distributing treatment
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protocols and informing the authorities (WHO, 2014c; WHO, 2015b). For meningococcal
meningitis, the alert threshold is as follows:


For population 30,000–100,000: three suspected cases per 100 000 inhabitants
a week (minimum of 2 cases in one week).



For population under 30,000: two suspected cases in one week or increased
incidence compared to previous non epidemic years.

Epidemic threshold: A higher level of incidence that triggers an epidemic
response, including mass vaccination, antibiotic distribution and raising public awareness
(WHO, 2014c). For meningococcal meningitis, the epidemic threshold is as follows:


For population 30,000–100,000: 10 suspected cases per 100 000 inhabitants a
week.



For population under 30,000: suspected cases in 1 week or doubling of the
number of cases in a 3-week period (e.g., week 1: 1 case, week 2: 2 cases,
week 3: 4 cases ).

Incidence: A measure of the frequency with which new cases of illness, injury, or
other health condition occurs among a population during a specified period (CDC,
2012c).
Incidence rate ratio (IRR): It is a measure of the frequency with which new cases
of illness, injury, or other health condition occur, expressed explicitly per a time frame.
Relative risk (RR): It is a useful measure to compare the prevalence or incidence
of disease between two groups. It is the ratio of prevalence or incidence in the exposed
group to the prevalence or incidence in the unexposed group (Sullivan, 2012).
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The confirmation of pathogens in meningitis surveillance is done by national or
WHO reference laboratories by investigating CSF samples. The confirmation is done
through culture or identification of pathogen. Identification can be done either by PCR or
immunochromatographic dipstick or latex agglutination of pathogens in the CSF or blood
(WHO; 2009a; WHO, 2009b; WHO, 2015b).
Data Analysis Plan
The inferential statistics were used to respond to the four research questions. The
first research question contributed to find the difference of meningitis suspected cased
before and after the introduction of MenAfriVac®. For that, IRRs of meningitis
suspected cases in vaccinated and unvaccinated populations were estimated using a
negative binomial regression model. The second research question helped to find the
difference of CFR of meningitis before and after the introduction of MenAfriVac®, for
that the Pearson’s chi-square was used to determine whether or not they were the
difference between CFR (> =10% or <10%). Additional IRR of deaths (fatal meningitis)
was calculated using negative binomial regression. The third research question
contributed to establish the degree of relationship between N. meningitidis A confirmed
and the MenAfriVac® immunization. The Pearson’s chi-square was used to determine
the degree of the relationship between N. meningitidis A confirmed and the
MenAfriVac® immunization in 21 out of the 26 countries of African meningitis belt
between 2010 and 2017. The fourth research question contributed to establish the
difference of meningitis epidemics caused by N. meningitidis A before and after the
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introduction of MenAfriVac®. The Pearson’s chi-square was used to estimate the relative
risk of districts to be in epidemic after the introduction of MenAfriVac®.
Descriptive and inferential statistics were conducted in this study using SPSS 21
version and Microsoft Excel 2013. Before conducting inferential statistics, cleaning data
was done for all research questions. A codebook created contain variable names, variable
labels, value labels, and a list of any changes.
The four RQs and hypotheses developed to assess the effects of MenAfriVac®
introduction in the 21 out of 26 African meningitis countries between 2010 and 2017
were as follows:
RQ1: What is the difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26 countries
of African meningitis belt between 2010 and 2017?
H01: There is no difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26
countries of African meningitis belt between 2010 and 2017.
Ha1: There is a difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26
countries of African meningitis belt between 2010 and 2017.
RQ2: What is the difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis belt
between 2010 and 2017?
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H02: There is no difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis
belt between 2010 and 2017.
Ha2: There is the difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis
belt between 2010 and 2017.
RQ3: What is the degree of relationship between the incidence of Neisseria
meningitidis serogroup A and the MenAfriVac® immunization in 21 out of the 26
countries of African meningitis belt between 2010 and 2017?
H03: There is no relationship between the incidence of Neisseria meningitidis
group A and the MenAfriVac® immunization in 21 out of the 26 countries of
African meningitis belt between 2010 and 2017.
Ha3: There is a relationship between the incidence of Neisseria meningitidis A
and the MenAfriVac® immunization in 21 out of the 26 countries of African
meningitis belt between 2010 and 2017.
RQ4: What is the difference in the frequency of meningitis epidemics caused by
Neisseria meningitidis A before and after the MenAfriVac® introduction in 21 out
of the 26 countries of African meningitis belt?
H04: There is no difference in the frequency of meningitis epidemics caused
by Neisseria meningitidis A before and after the MenAfriVac® introduction in
21 out of the 26 countries of African meningitis belt.
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Ha4: There is the difference in the frequency of meningitis epidemics caused
by Neisseria meningitidis A before and after the MenAfriVac® introduction in
21 out of the 26 countries of African meningitis belt.

Statistical Tests
To test the four hypotheses, descriptive and inferential statistics were chosen. This
study compared the risk of meningitis disease, CFR and deaths, N. meningitidis A
confirmed, and the occurrence of epidemics before and after MenAfriVac® introduction.
Negative binomial regression was used to calculate the IRR of meningitis suspected cases
and the deaths in MenAfriVac® vaccinated and unvaccinated populations. The relative
risk was calculated using Pearson’s chi-square to determine the degree of relationship
between the incidence of N. meningitidis A confirmed and the MenAfriVac®
immunization coverage, and the occurrence of health districts that reported epidemic due
to N. meningitidis A before and after the introduction of MenAfriVac®.
The dependent variables selected were the occurrence of N. meningitidis A or not
(another pathogen than N. meningitidis A, negative CSF sample), meningitis suspected
cases, deaths, and occurrence of meningitis epidemics. The independent variable was
MenAfriVac® vaccination status of health district (vaccinated after the introduction of
MenAfriVac®; vaccinated with any other polysaccharide vaccine that includes antigen A;
unvaccinated before the introduction of MenAfriVac®). Pathogens are being isolated
from CSF samples by culture or detected by latex agglutination test or PCR. The period
used for comparison was between 2004 and 2017. The following key parameter estimates
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were chosen: confidence interval chosen is 95% with Z =1.96, alpha = .05, type II error
=20%, power 0 80% with two tails.
Threats to Validity
The external validity requires a sound definition of the sample group and its
environment that include demographic data from surveillance. The generalizability was
feasible due to the large sample size, the sample was well-defined, and the
instrumentation related to the CSF sample testing was appropriate and followed by
laboratories involved in meningitis surveillance.
Countries selected for this study are being taken in consideration different biases
in the whole national surveillance systems including meningitis surveillance with the
main support of WHO. Routine testing of internal validity is implemented. Thus,
selection bias, information bias, and confounding bias were looked and identified. The
accuracy of surveillance information and completeness of information at all levels
contribute to reduce information bias. The meningitis case definition, deaths related, and
laboratory confirmation of CSF samples are being monitored by public health
professionals and WHO. It contributes to reduce selection bias (WHO, 2014c).
Concerning confounding bias, information given at health district level are verified to be
sure that the vaccination status of populations with another vaccine with antigen N.
meningitidis A is accurate.
The high quality of surveillance information depends on validity. Globally
African meningitis countries involved in this study are being used appropriately case
definition of meningitis and standards operating and procedures to testing CSF samples.
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The adequate use of standards operating and procedures for meningitis surveillance
including testing CSF samples contributed to provide validity of meningitis surveillance.
Meningitis surveillance that is being implemented by countries presents timeliness,
representation, sensitivity, and specificity.
Ethical Procedures
Two databases from WHO Inter-country Support Team of WEST Africa (IST
WA) websites were used. The request for the use of secondary data from these databases
was done in December 2016 to the regional director of WHO in Africa, and the approval
was given on December 19, 2017. The secondary data used for this study both are
anonymous, confidential, and will be secured hard and soft copies (password for folders).
Walden University gave IRB approval on February 7, 2018 (02-07-18-0409702). There
was no conflict of interest and, no incentive was taken for this study.
Summary and Conclusions
The research purpose of this study was to assess the effectiveness of the
introduction MenAfriVac® in 21 out of 26 countries of the meningitis belt from 2010 to
2017. Dependent variables selected were the occurrence of N. meningitidis A or not
(another pathogen than N. meningitidis A, negative CSF sample), meningitis suspected
cases, deaths, and occurrence of meningitis epidemics. The independent variable was
MenAfriVac® vaccination status of health district (vaccinated after the introduction of
MenAfriVac®; vaccinated with any other polysaccharide vaccine that includes antigen A;
unvaccinated before the introduction of MenAfriVac®). Pathogens are being isolated
from CSF samples by culture or detected by latex agglutination test or PCR. Secondary
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data were gathered from surveillance and MenAfriVac® coverage databases of WHO
ISTWA. To test the four hypotheses, descriptive and inferential statistics were chosen.
This study will compare the risk of meningitis disease, CFR and deaths, N. meningitidis
A confirmed, and the occurrence of epidemics before and after MenAfriVac®
introduction. Negative binomial regression was used to calculate the IRR of meningitis
suspected cases and deaths in MenAfriVac® vaccinated and unvaccinated populations.
The relative risk was calculated using Pearson’s chi-square to determine the degree of
relationship between the incidence of N. meningitidis A confirmed and the MenAfriVac®
immunization coverage, and the occurrence of health districts that reported epidemic due
to N. meningitidis A before and after the introduction of MenAfriVac®. The following
parameters estimated are chosen: confidence interval chosen is 95% with Z =1.96, alpha
= .05, type II error =20%, power = 80% with two tails.
The 21 African meningitis countries involved in this study used the appropriate
case definition of meningitis and the standards operating and procedures for testing CSF
samples (Djingarey et al., 2015; Lingani et al., 2015). The adequate use of standards
operating and procedures for meningitis surveillance including testing CSF samples
contributed to provide and therefore guarantee the validity of meningitis surveillance.
Meningitis surveillance that is being implemented by countries presents timeliness,
representation, sensitivity, and specificity. Ethics was taken into consideration.
Agreement for data collection of this study was given by WHO on December 19, 2017.
The IRB approval was received on February 7, 2018. The secondary data used for this
study were anonymous, confidential, and secured.
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The next chapter is titled results. This chapter comprises the following sections:
the introduction, the data collection, the descriptive and demographic characteristics, the
results (questions 1, 2, 3, and 4), and the summary.
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Chapter 4: Results
Introduction
The purpose of this study was to assess the effectiveness of the introduction of a
new meningococcal conjugate A vaccine called MenAfriVac® in 21 of the 26 countries
of the African meningitis belt between 2010 and 2017. I developed four RQs and
respective null and alternative hypotheses. They were as follows:
RQ1: What is the difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26 countries
of African meningitis bel between 2010 and 2017?
H01: There is no difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26
countries of African meningitis belt between 2010 and 2017.
Ha1: There is a difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26
countries of African meningitis belt between 2010 and 2017.
RQ2: What is the difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis belt
between 2010 and 2017?
H02: There is no difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis
belt between 2010 and 2017.

60
Ha2: There is the difference in the CFR of meningitis disease before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis
belt between 2010 and 2017.
RQ3: What is the degree of relationship between the incidence of Neisseria
meningitidis serogroup A and the MenAfriVac® immunization in 21 out of the 26
countries of African meningitis belt between 2010 and 2017?
H03: There is no relationship between the incidence of Neisseria meningitidis
group A and the MenAfriVac® immunization in 21 out of the 26 countries of
African meningitis belt between 2010 and 2017.
Ha3: There is a relationship between the incidence of Neisseria meningitidis A
and the MenAfriVac® immunization in 21 out of the 26 countries of African
meningitis belt between 2010 and 2017.
RQ4: What is the difference in the frequency of meningitis epidemics caused by
Neisseria meningitidis serogroup A before and after the MenAfriVac®
introduction in 21 out of the 26 countries of African meningitis belt?
H04: There is no difference in the frequency of meningitis epidemics caused
by Neisseria meningitidis A before and after the MenAfriVac® introduction in
21 out of the 26 countries of African meningitis belt.
Ha4: There is the difference in the frequency of meningitis epidemics caused
by Neisseria meningitidis A before and after the MenAfriVac® introduction in
21 out of the 26 countries of African meningitis belt.

61
This chapter includes a description of time frame, data collection, any
discrepancies in data, descriptive and demographic characteristics, results of the study,
and findings.
Data Collection
I retrieved the data for this study between February 10 and February 28, 2018,
from WHO ISTWA databases and WHO websites. The secondary data retrieved
concerned meningitis surveillance between 2004 and 2017 and MenAfriVac® vaccine
introduction from 2010 to 2017. The secondary data from meningitis surveillance
concerned especially meningitis suspected cases that fit the case definition, CFR, CSF
samples tested in laboratories, and the meningitis epidemics due to N. meningitidis A
reported by health districts using meningitis epidemic threshold. Concerning the
MenAfriVac® introduction, information gathered mainly concerned vaccination
coverage, the quality of implementation and evaluation of mass vaccination campaigns,
and routine immunization programmes. The data retrieved were aggregated and sent by
countries on a regular basis. Data were sent on a weekly basis concerning meningitis
surveillance, and monthly regarding MenAfriVac® immunization activities. The data
collected were prior treated, consolidated, harmonized, and validated at the country level
before sending to WHO ISTWA. To improve the quality of data, WHO, CDC, and
UNICEF provided technical support. Reference documents on standards were operating,
and procedures for meningitis surveillance and MenAfriVac® introduction activities
were developed. Between 2002 and 2017, training on data management and enhanced
surveillance were regularly done in the countries of the African meningitis belt. Data
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quality audit and supervision were done to improve the quality of surveillance and
vaccination data from health facilities directly to the central level (WHO, 2014c; WHO &
CDC, 2010). The procedures stated above aimed to assure the accuracy of data. I
exported the data to SPSS (Version 21) for analysis. I created the new dataset of the study
called MenA_dataset. They were no discrepancies in data collection. Almost 2.5 % of
data were missing because few countries didn’t share the data with WHO IST WA.
The dependent variables selected were the occurrence of N. meningitidis A,
laboratory-confirmed or not, meningitis suspected cases, CFR, deaths, and occurrence of
meningitis epidemics due to N. meningitidis A as reported by health districts. The
independent variable was MenAfriVac® vaccination status of people living in health
districts (vaccinated after the introduction of MenAfriVac®; vaccinated with any other
polysaccharide vaccine that includes antigen A; unvaccinated before the introduction of
MenAfriVac®). The statistical assumptions for negative binomial regression were met.
The conditional means were not equal to the conditional variances, and the outcome
variables were over-dispersed. The distribution was a Poisson distribution, where the
mean and variance differ from one another. In this study, observations were independent
variables. The statistical assumptions for Pearson’s Chi-Square were met because the
observations for the two-way contingency table analysis were independent of each other,
and all the expected occurrences of the crosstab were greater than five.
Descriptive and Demographic Characteristics
The population of this study was characterized by people living in 1,713
meningitis highest risk health districts of 21 countries of the African meningitis belt. The
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21 countries had 3,817 health districts. Meningitis highest risk health districts were
selected to introduce MenAfriVac®. The selection was made through the risk assessment
using the district prioritization tool developed by WHO (Cibrelus et al., 2015). The 21
countries that were participants of this study were Mali, Burkina Faso, Cameroon,
Central Africa Republic, Chad, Benin, Cote d’Ivoire, Togo, Mauritania, Niger, Nigeria,
Ghana, Gambia, Guinea, Guinea Bissau, Ethiopia, Sudan, South Sudan, Senegal, and
Uganda. The total estimated population was 407,958,506 persons. People who were
vaccinated with MenAfriVac® were aged 1-29 years old because they were the highest
risk for meningitis infection caused by N. meningitidis A. The age group 1-29 years old
represented almost 70% of the total population. The estimated target population for
MenAfriVac® vaccination was 285,570,957 people. Between 2010 and 2017,
286,995,073 were immunized with MenAfriVac® thus there was 100% administrative
coverage (see Table 1). The target population of this study was large and representative.
The findings can be generalized over the African meningitis belt countries.
Before MenAfriVac®, people were immunized with other multivalent
polysaccharide vaccines (AC, ACW, ACW) that included antigen A against N.
meningitidis A. These polysaccharides vaccines were mainly administrated to populations
to respond to meningitis epidemics and during the pilgrimage to Mecca. People are being
vaccinated mostly within meningococcal meningitis epidemics. These vaccines protect
for three years with no properties on the carriage, whereas MenAfriVac® protects both
the individual and the community. It reduces the carriage of N. meningitidis A, and so
increases the herd immunity (WHO, 2015a). Table 2 shows that an estimated
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304,155,728 persons were vaccinated against N. meningitidis A with polysaccharide
vaccines. Between 2008 and 2017, 286,995,073 people (94.4%) were immunized with
MenAfriVac®, whereas 17,160,655 (5.6%) were protected with the other polysaccharides
vaccines (AC, ACW, ACW).
Table 2
People Vaccinated With Vaccines That Include Antigen A 2008-2017

Countries

Estimated people
vaccinated with other
multivalent vaccines that
include antigen A 20082017

Total

%

Number

%

Number

%

People vaccinated with
MenAfriVac 2010-2017

Number
Benin

2718459

83.7

527631

16.3

3246090

100.0

Burkina Faso

15295276

87.3

2220000

12.7

17515276

100.0

Cameroon

6510729

99.9

7200

0.1

6517929

100.0

Central African Republic

3220358

98.8

40000

1.2

3260358

100.0

Chad

8732151

79.8

2215200

20.2

10947351

100.0

Cote d’Ivoire
Democratic Republic of
Congo

2764839

94.4

163000

5.6

2927839

100.0

18058535

100.0

0

0.0

18058535

100.0

Ethiopia

60996186

99.8

120560

0.2

61116746

100.0

Gambia

1228419

100.0

0

0.0

1228419

100.0

Ghana

3705081

91.2

356540

8.8

4061621

100.0

Guinea

2442566

97.5

63075

2.5

2505641

100.0

Guinea Bissau

1150136

100.0

0

0.0

1150136

100.0

Mali

14593475

99.8

34348

0.2

14627823

100.0

Mauritania

1561720

100.0

0

0.0

1561720

100.0

Niger

10575365

70.9

4349540

29.1

14924905

100.0

Nigeria

87062324

95.9

3703340

4.1

90765664

100.0

Senegal

4216691

100.0

0

0.0

4216691

100.0

South Sudan

4023659

100.0

0

0.0

4023659

100.0

Sudan

28232735

92.8

2176353

7.2

30409088

100.0

Togo

2764839

77.9

782918

22.1

3547757

100.0

Uganda

7141530

94.7

400950

5.3

7542480

100.0

Total

286995073

94.4

17160655

5.6

304155728

100.0

Note. Source WHO
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Table 3 shows the descriptive analyses for meningitis suspected cases, deaths, N.
meningitidis A laboratory-confirmed, and health districts that reported N. meningitidis A
epidemics from 2004 to 2017.
Table 3
Meningitis Incidence, N. Meningitidis A Confirmed, Deaths, CFR, Epidemics
Items

Countries

N

Missing data

Median

Minimum

Maximum

Meningitis
Suspected cases

Country

485664

12

416

0

56128

28343

18938

90996

All
Deaths due to
meningitis disease

Country

N. meningitidis A
Confirmed cases

Country

Crude Fatality Rate
(CFR)

Country

Health districts
reported N.
meningitidis A
epidemics

Country

42004

16

All
6659

0

All

All

NA

16

516

0

All

46

0

2488

2547

1418

5507

0

0

1460

210

3

2066

8.84

0.00

76.27

8.60

6.05

13.82

0

0

175

18

0

207

Meningitis Suspected Cases
Table 3 shows that 485,664 cumulative suspected meningitis cases had been
reported between 2004 and 2017 in the 21 countries selected for this study (out of the 26
of the African meningitis belt). Table 3 also shows that the median for each country was
416, and the range was 0–56,128. For all the 21 countries the median of meningitis
suspected cases was 28,343, and the range was 18,936–90,996. The higher number of
suspected meningitis cases was 90,996 reported in 2009 and the lowest number of
suspected meningitis cases was18,939 reported in 2016. Figure 2 shows a decline of
meningitis suspected cases after 2010 in the 21 countries selected for the study (out of the
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26 of the African meningitis belt). Meningitis suspected cases remained high and
therefore a public health problem after 2010. Between 2010 and 2017, the highest
number of meningitis suspected cases reported was 29,335 in 2012, and the range was
18,938–29,335.
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Figure 2. Meningitis suspected cases 2004-2017.

Deaths and Crude Fatality Rate
Table 3 shows that 42,004 deaths caused by meningitis disease (fatal meningitis)
have been reported between 2004 and 2017 in the 21 countries selected for this study.
Table 3 shows that the median number of deaths caused by meningitis disease for each
country was 46, and the range was 0–2,488). Whereas for all the 21 countries selected for
this study, the median of deaths was 2,547, and the range (1,418–5,507). Table 3 shows
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that the median of CFR for each country was 8.84, and the range (0–76.27). Whereas for
all countries, the median of CFR was 8.6, and the range (6.05-13.82).Figure 2 shows that
the highest number of deaths caused by meningitis disease was 5,507 reported in 2009.
The lowest number of deaths was 1,418 reported in 2016. The number of meningitis
deaths was higher before 2010. The highest number of meningitis deaths was 5,507
reported in 2004. Figure 3 shows a decline of meningitis deaths and CFR after 2010. The
CFR was higher before 2010; most were over 10%. The highest CFR was 14% reported
in 2004, and the lowest CFR was 6% reported in 2017.
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Figure 3. Incidence of meningitis deaths and crude fatality rate 2004-2017.

N. Meningitidis A Confirmed Cases
The Table 3 shows that 6,776 N. meningitidis A laboratory-confirmed cases have
been reported between 2004 and 2017 in the 21 countries selected for this study out of the
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26 of the African meningitis belt. Figure 3 shows that the incidence of N. meningitidis A
confirmed case was higher before 2010. The highest N. meningitidis A was 2066 reported
in 2009. Whereas the lowest incidence of meningitis deaths was three, reported in 2017.
The median of N. meningitidis A laboratory-confirmed cases for each country was 0, and
the range (0-1,460). Whereas for all the 21 countries selected for the study the median of
N. meningitidis A laboratory-confirmed case was 210, and the range (3 - 2,066). Figure 4
shows N. meningitidis A reported decline significantly after 2010 with the introduction of
MenAfriVac®.
2500

N. meningitis A confirmed cases

2066

N. meningitidis A
confirmed cases

2000

1500

1102
954
1000

779
682
484

500
214

170

88

23

6

2013

2014

80

9

2

2016

2017

0
2004

2005

2006

2007

2008

2009

2010

2011

2012

2015

Years

Figure 4. N. meningitidis A confirmed 2004-2017.
Figure 5 shows the decline of N. meningitidis A since 2010 and the predominance
of other pathogens as follows S. Pneumoniae, N. meningitidis W135, and N. meningitidis
C. Table 4 shows that meningococcal disease remains predominant and a public health
problem. 15,885 (62.06%) out of 25,596 meningitis pathogens were confirmed between
2010 and 2017.
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Figure 5. Meningitis pathogens laboratory confirmed 2004-2017.
Table 4
Meningitis Pathogens Profile

Years

N.menin
gitidis A

N.
menin
gitidis
B

N.
menin
gitidis
X

N.
menin
gitidis
Y

Other N.
menin
gitidis

S.pne
umoni
ae

Hemo
philus
influe
nza b

Other
Patho
gens

Total

2004

682

0

125

0

0

0

48

447

104

0

1406

2005

170

0

2006

954

0

33

0

0

0

53

323

125

61

765

34

0

0

0

441

234

95

60

1818

2007

779

0

62

0

0

0

9

297

74

50

1271

2008

1102

2009

2066

0

7

0

0

0

65

243

48

39

1504

0

167

0

0

0

29

355

37

74

2728

2010
2011

484

0

727

4

55

0

14

351

47

25

1707

214

0

487

0

128

0

4

748

40

27

1648

2012

88

1

1009

4

138

1

31

539

45

25

1881

2013

23

2

237

10

15

0

57

466

38

55

903

2014

6

2

286

48

11

1

34

656

50

76

1170

2015

80

2

545

1224

20

0

62

734

40

243

2950

2016

9

1

719

375

68

6

296

1062

87

416

3039

2017

2

0

263

891

333

2

40

809

136

330

2806

Total

6659

8

4701

2556

768

10

1183

7264

966

1481

25596

Countries

N.
N.
menin menin
gitidis gitidis
W135
C
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Health Districts Reported N. Meningitidis A Epidemics
The Table 3 shows that 515 health districts reported N. meningitidis A epidemics
between 2004 and 2017 in 21 countries selected for this study out of the 26 of the African
meningitis belt. The figure 4 shows that the highest number of health districts that
reported N. meningitidis A was 207 reported on 2009. Whereas, the lowest number of
health districts that reported N. meningitidis A was 0 reported between 2015 and
2017.The median of N. meningitidis A for each country was 0, and the range (0-175).
Whereas, for all the 21 countries selected for this study the median of health districts that
reported N. meningitidis A epidemic was 18, and the range (0-207). The figure 6 shows
the decline of meningitis epidemics due to N. meningitis A reported since 2010. Since
2015 any health district reported N. meningitis A epidemic.

250

Health districts
in N.
meningitidis A…

207
200

Epidemics

150
80

100

51
50

20

56
4731
15

6

1

1

0

0

0

0
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Years

Figure 6. Health districts that reported N. meningitidis A epidemics 2004-2017.
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Results
Descriptive and inferential statistics were done using SPSS statistics 21. The
negative binomial regression was used to calculate IRR to calculate the difference of
meningitis suspected cases and deaths before and after MenAfriVac® introduction in 21
out of the 26 countries of African meningitis belt between 2010 and 2017. IRR was also
calculated to determine whether or not they were a reduction of meningitis suspected
cases and deaths. The Pearson’s chi-square was used to determine whether or not they
were the difference between CFR and districts that reported epidemics due to N.
meningitidis A before and after the introduction of MenAfriVac. The Pearson’s chisquare was also used to determine the degree of the relationship between the incidence of
Neisseria meningitidis serogroup A and the MenAfriVac® immunization in 21 out of the
26 countries of African meningitis belt between 2010 and 2017.
Research Question 1
RQ1: What is the difference of incidence rate of suspected cases of meningitis
disease before and after MenAfriVac® introduction in 21 out of the 26 countries
of African meningitis belt between 2010 and 2017?
Table 5 shows that after the introduction of the MenAfriVac®, there was a 39%
decline of incidence rate of meningitis suspected cases (IRR 0.61, 95% CI 0.48 – 0.79, p
< .001), with heterogeneity observed by country. The null hypothesis was rejected
because it was less than .05. Therefore, there is a difference in incidence rate of the
suspected cases of meningitis disease before and after MenAfriVac® introduction in 21
out of the 26 countries of African meningitis belt between 2010 and 2017. The difference
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of incidence rate of the meningitis suspected cases was significant (p < .05) in Burkina
Faso, Nigeria, South Sudan, and Sudan.
Table 5
Incidence Rate Ratio for Meningitis Suspected Cases 2004-2017
IRR

95%CI

p

All

0.61

0.48 - 0.79

.000

Benin

1.78

0.60 - 5.32

0.301

Burkina Faso

0.33

0.12 - 0.96

.000

Cameroon

1.99

0.69 - 5.69

0.197

Central African republic

2.88

0.38 - 22.06

0.308

Chad

0.19

0.02 - 1.45

0.11

Democratic republic of Congo

0.34

0.08 - 1.52

0.157

Ethiopia

11.17

3.50 - 35.68

0.014

Gambia

0.87

0.29 - 2.64

0.881

Ghana

1.45

0.50 - 4.20

0.488

Guinea

0.61

0.17 - 2.26

0.461

Guinea- Bissau

7.31

1.59 - 33.6

0.011

Ivory coast

0.5

0.16 - 1.60

0.244

Mali

0.51

0.18 - 1.48

0.217

Mauritania

0.35

0.09 - 1.33

0.125

Niger

0.49

0.17 - 1.42

0.188

Nigeria

0.25

0.09 - 0.70

.000

Senegal

3.28

1.14 - 9.49

0.028

South Sudan

0.02

0.005 - 0.10

.000

Sudan

0.11

0.04 - 0.35

0.033

Togo

1.75

0.55 - 5.60

0.343

Uganda

0.25

0.03 - 1.97

0.187

Note. IRR = Incidence Rate Ratio. CI = Confident Interval. NA = Not Applicable. p = p-value.

Research Question 2
RQ2: What is the difference in the CFR of meningitis before and after
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis belt
between 2010 and 2017?
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Table 7 shows that X2 (1) = 14.18, p = .000. The null hypothesis was rejected
because p was less than .05. Therefore, there was a difference in the meningitis CFR
before and after MenAfriVac® introduction in 21 out of the 26 countries of African
meningitis belt. The table 8 shows that there was 46% decline of risk to report high CFR
(>=10%) after the MenAfriVac® immunization (RR 0.547, 95% CI 0.40 – 0.74). Table 9
shows that after the introduction of the MenAfriVac® vaccine, there was a 49% decline
of meningitis deaths (IRR 0.51, 95% CI 0.40 – 0.66, p < .001), with heterogeneity
observed by country. The null hypothesis was rejected because p was less than .05.
Therefore, there was a difference in fatal meningitis before and after MenAfriVac®
introduction in 21 out of the 26 countries of African meningitis belt. The difference in the
fatal meningitis was significant (p < .05) in Ivory Coast, Mali, Mauritania, Nigeria, South
Sudan, and Sudan.

Table 6
MenAfriVac Introduction and CFR Cross Tabulation

Factor (MenAfriVac
introduction)

Total

Count
After MenAfriVac % within Factor
introduction
% within CFR
% of total
Count
Before
% within Factor
MenAfriVac
% within CFR
introduction
% of total
Count
% within Factor
% within CFR
% of total

CFR
>=10%
101a
71.6%
61.2%
36.9%
64a
48.1%
38.8%
23.4%
165
60.2%
100.0%
60.2%

Total
<10%
40b
28.4%
36.7%
14.6%
69b
51.9%
63.3%
25.2%
109
39.8%
100.0%
39.8%

141
100.0%
51.5%
51.5%
133
100.0%
48.5%
48.5%
274
100.0%
100.0%
100.0%
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Table 7
Chi-Square Tests for CFR and MenAfriVac® Introduction

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher’s Exact Tests
N of Valid Cases

Value

df

15.792a
14.826
15.944

1
1
1

Asymp. Sig.
(2-sided)
.000
.000
.000

Exact Sig.
(2-sided)

Exact Sig.
(1-sided)

.000

.000

274

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 39.12.
b. Computed only for a 2x2 table.

Table 8
Risk Estimate of CFR and MenAfriVac® Introduction
Value
Odds Ratio for Factor (After MenAfriVac
introduction / Before MenAfriVac introduction)
For cohort CFR = No
For cohort CFR = Yes
N of Valid Cases

2.722
1.489
.547
274

95% Confidence Interval
Lower
Upper
1.652
4.487
1.213
.401

1.827
.745
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Table 9
Incidence Risk Ratio of Meningitis Deaths 2004-2017
IRR

95%CI

All

0.51

0.40 - 0.66

.000

Benin

1.13

0.38 - 3.38

0.301

Burkina Faso

0.38

0.13 - 1.10

0.073

1

0.34 - 2.87

0.99

Central African republic

1.72

0.22 - 13.27

0.308

Chad

0.16

0.02 - 1.27

0.11

Democratic republic of Congo

0.27

0.06 - 1.19

0.157

Ethiopia

0.74

0.23 - 2.42

0.620

Gambia

2.48

0.69 - 8.80

0.162

Ghana

0.91

0.31 - 2.64

0.488

Guinea

0.39

0.10 - 1.49

0.461

Guinea-Bissau

NA

Ivory coast

0.27

0.08 - 0.89

0.032

Mali

0.29

0.10 - 0.86

0.026

0

0.00 - 0.00

.000

Niger

0.61

0.21 - 1.77

0.188

Nigeria

0.24

0.08 - 0.69

0.009

Senegal

1.61

0.53 - 4.92

0.400

South Sudan

0.012

0.002 - 0.08

.000

Sudan

0.08

0.02 - 0.26

.000

Togo

0.95

0.29 - 3.06

0.343

Uganda

0.59

0.07 - 5.25

0.638

Cameroon

Mauritania

p

Note. IRR = Incidence Rate Ratio. CI = Confident Interval. NA = Not Applicable. p = pvalue.

Research Question 3
RQ3: What is the degree of relationship between the incidence of Neisseria
meningitidis serogroup A and the MenAfriVac® immunization in 21 out of the 26
countries of African meningitis belt between 2010 and 2017?
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Table 11 shows that χ2 (1) = 11039.49, p = 0.000. The null hypothesis was
rejected because p was less than .05. Therefore, there was a relationship between the
incidence of Neisseria meningitidis serogroup A and the MenAfriVac® immunization in
21 out of the 26 countries of African meningitis belt between 2010 and 2017. Table 12
shows that
Phi = 0.657, P=0.000 that means the strength of the relationship is high between the
incidence of Neisseria meningitidis serogroup A and the MenAfriVac® immunization in
21 out of the 26 countries of African meningitis belt between 2010 and 2017. Table 13
shows 99% decline of risk to report N. meningitidis A after the introduction of
MenAfriVac® (RR 0.01, 95% CI 0.08-0.013).
Table 10
MenAfriVac® Introduction and N. Meningitidis A Cross Tabulation

Factor
(MenAfriVac®
introduction)

Total

After
MenAfriVac®
introduction

Before
MenAfriVac®
introduction

Count
Expected Count
% within Factor
% within N. meningitidis A
% of total
Standard Residual
Count
Expected Count
% within Factor
% within N. meningitidis A
% of total
Standard Residual
Count
Expected Count
% within Factor
% within N. meningitidis A
% of total

N. meningitidis A
No
Yes
14310
87
10651.5
3745.5
99.4%
0.6%
75.6%
1.3%
55.9%
0.3%
35.4
-59.8
4627
6572
8285.5
2913.5
41.3%
58.7%
24.4%
98.7%
18.1%
25.7%
-40.2
67.8
18937
18937
18937.0
18937.0
73.6%
74.0%
100.0%
100.0%
73.6%
74.0%

Total
14397
14397.0
100.0%
56.2%
56.2%
11199
11199.0
100.0%
43.8%
43.8%
6659
6659.0
26.0%
100.0%
26.0%

77
Table 11
Chi-Square Tests for MenAfriVac® Introduction and N. Meningitidis A
Valuedf
Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher’s Exact Tests
N of Valid Cases

11039.494a1
11036.4771
13096.3701

Asymp. Sig.
(2-sided)
.000
.000
.000

Exact Sig.
(2-sided)

Exact Sig.
(1-sided)

.000

.000

25596

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is
2501.37.
b. Computed only for a 2x2 table

Table 12
Symmetry Measures for MenAfriVac® Introduction and N. Meningitidis A

Nominal by Nominal

Phi
Cramer’s V
Contingency Coefficient

N of Valid Cases

Value
.657
.657
.549
25596

Approx. Sig
.000
.000
.000
25596

Table 13
Risk Estimate for MenAfriVac® Introduction and N. Meningitidis A
Value
Odds Ratio for Factor (After MenAfriVac®

233.625

95% Confidence Interval
Lower
Upper
188.598
289.401

®

introduction / Before MenAfriVac introduction)
For cohort N. meningitidis A = No
For cohort N. meningitidis A = Yes
N of Valid Cases

2.406
.010
25596

2.353
.008

2.460
.013

Research Question 4
RQ4: What is the difference in the frequency of meningitis epidemics caused by
Neisseria meningitidis A before and after the MenAfriVac® introduction in 21 out
of the 26 countries of African meningitis belt?
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Table 15 shows that χ2 (1) = 595.351, p = 0.000. The null hypothesis was rejected
because p was less than .05. Therefore, there was a difference in the frequency of
meningitis epidemics caused by Neisseria meningitidis A before and after the
MenAfriVac® introduction in 21 out of the 26 countries of African meningitis belt. Table
16 shows 99.6% decline of risk for a health district to be in epidemic due to N.
meningitidis A after the introduction of MenAfriVac® (RR 0.004, 95% CI 0.001-0.016).
Table 14
MenAfriVac® Introduction and District in N. Meningitis A Epidemics
District in N. meningitis A
Epidemics

Factor
(MenAfriVac®
introduction)

Total

After
MenAfriVac®
introduction

Before
MenAfriVac®
introduction

Count
Expected Count
% within Factor
% within District in N. meningitis A Epidemics
% of total
Standard Residual
Count
Expected Count
% within Factor
% within District in N. meningitis A Epidemics
% of total
Standard Residual
Count
Expected Count
% within Factor
% within district in N. meningitis A Epidemics
% of total

No

Yes

1711
1456.0
99.9%
58.8%
49.9%
6.7
1201
1456.0
70.1%
41.2%
35.1%
-6.7
2912
2912.0
85.0%
100.0%
85.0%

2
257.0
0.1%
0.4%
0.1%
-15.9
512
257.0
29.9%
99.6%
14.9%
15.9
514
514.0
15.0%
100.0%
15.0%

Total
1713
1713.0
100.0%
50.0%
50.0%
1713
1713.0
100.0%
50.0%
50.0%
3426
3426.0
100.0%
100.0%
100.0%
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Table 15
Chi-Square Tests for MenAfriVac® Introduction and District in N. Meningitis A
Epidemics

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher’s Exact Tests
N of Valid Cases

Value

df

595.351a
593.019
776.149

1
1
1

Asymp.
Sig.
(2-sided)
.000
.000
.000

Exact Sig.
(2-sided)

Exact Sig.
(1-sided)

.000

.000

3426

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is
257.50. b. Computed only for a 2x2 table

Table 16
Risk Estimate for MenAfriVac® Introduction and District in N. Meningitis A Epidemics
95% Confidence Interval
Value
Odds Ratio for Factor (After
MenAfriVac® introduction / Before
MenAfriVac® introduction)
For cohort district in N. meningitis A
Epidemics = No
For cohort district in N. meningitis A
Epidemics = Yes
N of Valid Cases

Lower

Upper

364.709

90.789

1465.084

1.425

1.381

1.469

.004

.001

.016

3426

Summary
In this chapter, descriptive and inferential statistics were presented above on the
line of the four research questions. The statistical assumptions for negative binomial
regression and Pearson’s Chi-square were met. They were no data discrepancies. After
2010, the descriptive analyses showed into meningitis belt decline of incidence rate of the
meningitis suspected cases, fatal meningitis, N. meningitidis A confirmed cases, and
epidemics due to N. meningitidis A. The trends found might be related to the introduction
of MenAfriVac in the 21 out of 26 countries of the African meningitis belt. Before 2010,
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N. meningitidis A was predominant after 2010, N. meningitidis A declined and the
predominant meningitis pathogens found were S. Pneumoniae, N. meningitidis W135,
and N. meningitidis C N. meningitidis represent almost 55% out of all meningitis
pathogens laboratory-confirmed between 2010 and 2017.
The inferential analyses showed that after the introduction of the MenAfriVac®
vaccine:
1. There was a 39% decline of incidence rate of meningitis suspected cases (IRR
0.61, 95% CI 0.48 – 0.79, p < .001), with heterogeneity observed by country.
2. There was a difference in the meningitis CFR before and after MenAfriVac®
introduction in 21 out of the 26 countries of African meningitis belt. After the
introduction of MenAfriVac., there was a 46% decline in risk to report high
CFR (>10%) after the MenAfriVac® immunization (RR 0.547, 95% CI 0.40 –
0.74).
3. There was a 49% decline of fatal meningitis (IRR 0.51, 95% CI 0.41 – 0.68, p
< .001), with heterogeneity observed by country.
4. There was a high degree of relationship between the incidence of N. meningitidis A and
the MenAfriVac® immunization in 21 out of the 26 countries of African meningitis belt
between 2010 and 2017, (χ2 (1) = 11039.49, p = 0.000, Phi = 0.657, P=0.000).
5. After the introduction of MenAfriVac®, there was 99% decline in the risk of N.
meningitidis A (RR 0.01, 95% CI 0.08-0.013).
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6. After the introduction of MenAfriVac® in the meningitis belt, there was 99.6% decline of
risk for a health district to report epidemic caused by N. meningitidis A (RR 0.004, 95%
CI 0.001-0.016).
In summary, the introduction of MenAfriVac in African meningitis belt reduced
significantly the incidence rate of meningitis suspected cases, meningitis CFR, deaths due
to meningitis disease, and epidemics caused by N. Meningitidis A.
The next chapter presents discussion, recommendations, and conclusions of the
study.
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Chapter 5: Discussion, Recommendations, and Conclusions
Introduction
The purpose of this study was to assess the effectiveness of the introduction of a
new meningococcal conjugate A vaccine called MenAfriVac® in 21 out of 26 countries
of the African meningitis belt between 2010 and 2017. The study was quasi-experimental
research with an interrupted time series quantitative research design. The interrupted
times series design was used to assess the effect of the introduction of the MenAfriVac®
between 2010 and 2017 in 21 countries selected for this study using data from meningitis
surveillance and N. meningitidis A coverage from 2004 to 2017. The major preview
sections of this chapter are the introduction, key findings of the study, interpretation of
findings, limitations of the study, recommendations for future research, social change
implications, and the conclusion.
Key Findings of the Study
With the introduction of MenAfriVac® between 2010 and 2017 in the 21
countries selected out of the 26 of the African meningitis belt, the study showed:
1. a 39% decline of incidence rate of the meningitis suspected cases (IRR 0.61, 95%
CI 0.48 – 0.79, p < .001), with heterogeneity observed by country;
2. a 46% decline of risk to report high CFR (> = 10%) after the MenAfriVac®
immunization (RR 0.547, 95% CI 0.40 – 0.74);
3. a 49% decline of fatal meningitis (IRR 0.51, 95% CI 0.41 – 0.68, p < .001), with
heterogeneity observed by country;
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4. a high degree of relationship between N. meningitidis A reported and the
MenAfriVac® immunization between 2010 and 2017 in 21 out of the 26 countries
of African meningitis belt, (χ2 (1) = 11039.49, p = 0.000, Phi = 0.657, P=0.000);
5. a 99% decline in the risk of N. meningitidis A after the introduction of
MenAfriVac® (RR 0.01, 95% CI 0.08-0.013); and
6. a 99.6% decline of risk for a health district to report epidemic caused by N.
meningitidis A after the introduction of MenAfriVac, (RR 0.004, 95% CI 0.0010.016 ).
In summary, the study found that the introduction of MenAfriVac® in African
meningitis belt reduced significantly the incidence rate of the meningitis suspected cases,
meningitis CFR, deaths due to meningitis disease, and epidemics caused by N.
Meningitidis A. Before 2010, N. meningitidis A was predominant. The study also showed
that after the introduction of MenAfriVac® in 2010 and until 2017, the predominant
meningitis pathogens were S. Pneumoniae, N. meningitidis W135, and N. meningitidis C.
N. meningitidis represented almost 62.06% out of all meningitis pathogens laboratoryconfirmed between 2010 and 2017.
Interpretation of Findings
I defined four RQs to assess the effects of the introduction of MenAfriVac® in 21
out of 26 countries of the African meningitis belt before and after 2010. All the null
hypotheses were rejected. In the following sections, I present the key findings compared
with those found in literature review in four areas related to the research questions.
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Key Findings
Meningitis suspected cases reported before and after MenAfriVac®
introduction. The study found 39% decline of incidence rate of meningitis suspected
cases (IRR 0.61, 95% CI 0.48 – 0.79, p < .001) after the introduction of MenAfriVac®,
with heterogeneity observed by country. These results confirm the same trend of
reduction of meningitis suspected cases found in the literature review (Carod, 2015;
Daugla et al., 2013; Diallo et al., 2017; Diomandé et al., 2015; Novak et al., 2012; PATH,
2013; Trotter et al., 2017; WHO, 2013 March 12; WHO, 2016a). However, Trotter et al.
(2017) found a 57% decline of meningitis suspected cases in nine countries (Benin,
Burkina Faso, Chad, Ivory Coast, Ghana, Mali, Niger, Nigeria, and Togo) 5 years after
introduction of MenAfriVac® (IRR 0.43, 95% CI 0.41-0.45, p < .001). In Burkina Faso,
Novak et al. (2012) found 71% decline of meningitis suspected cases one year after the
introduction of MenAfriVac® (hazard ratio 0.29, 95% CI 0.28-0.30) and Trotter et al.
(2017) found a decline of 70% 5 years after the introduction of MenAfriVac® (IRR 0.30,
95%CI 0.29-0.31). This study found a 77% decline 7 years after the introduction of
MenAfriVac® in Burkina Faso (IRR 0.33, 95% CI 0.12-0.96, p < .001). Conversely,
Trotter et al. (2017) and Daugla et al. (2013) found respectively 91% (IRR 0.086, 95%CI
0.077-0.097) and 94% (p < 0.0001) of reduction of meningitis deaths in Chad. This study
also found that the decrease of meningitis deaths before and after the introduction of
MenAfriVac® was significant (IRR 0.19, 95% CI 0.02-1.45).
Meningitis CFR and deaths reported before and after MenAfriVac®
introduction. The study found a 46% decline of risk to report high CFR (>= 10%) after
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the MenAfriVac® immunization (RR 0.547, 95% CI 0.40 – 0.74) and 49% decline of fatal
meningitis (IRR 0.51, 95% CI 0.41 – 0.68, p < .001), with heterogeneity observed by
country. The results confirm the findings of the literature (Diallo et al., 2017; Novak et
al., 2012; WHO, 2016a). The decline of high CFR can be explained by the modification
of treatment protocol that was included since 2014 ceftriaxone. Diallo et al. (2017) found
between 2011 and 2015 in Burkina Faso that CFR was 8%. WHO (2016a) found between
1995 and 2014 in meningitis belt countries CFR = 10%. Conversely, Collard et al. (2013)
found in Niger an increase of CFR from 6.7% in 2008 to 12.2% in 2011. Concerning
meningitis deaths, this study found that in Niger there was no significant difference of
fatal meningitis before and after the introduction of MenAfriVac® (IRR 0.61, 95% CI
0.21 – 1.77, p = 0.188) probably because of the high number of meningitis deaths during
meningitis epidemics from 2015 to 2017. Novak et al. (2012) found in Burkina Faso 1
year after the introduction of MenAfriVac® a 64% decline in risk of fatal meningitis.
However, this study found that 7 years after the introduction of MenAfriVac®, there was
a significant difference of reduction of fatal meningitis (IRR 0.38, 95% CI 0.13 – 1.77).
The relationship between the N. meningitidis A reported and the
MenAfriVac® immunization in 21 out of the 26 countries of the African meningitis
belt. This study found a high degree of relationship between N. meningitidis A reported
and the MenAfriVac® immunization between 2010 and 2017 in 21 out of the 26 countries
of the African meningitis belt, (χ2 (1) = 11039.49, p = 0.000, Phi = 0.657, P=0.000). The
study also found 99% decline in the risk of N. meningitidis A after the introduction of
MenAfriVac® (RR 0.01, 95% CI 0.08-0.013). These results globally confirmed the
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findings of the literature. The findings showed the relationship between the reduction of
N. meningitidis A reported and the MenAfriVac® immunization in African meningitis
belt countries (Carod, 2015; Collard et al., 2013; Daugla et al., 2013; Diallo et al., 2017;
Diomandé et al., 2015; GAVI, 2016; LaForce et al., 2017; Lingani et al., 2015; Meyer,
2017; Novak et al., 2012; PATH and WHO, 2016; Retchless et al., 2016; Sambo et al.,
2015; Stuart, 2018; Trotter et al., 2017; WHO, 2015a). The findings in the literature did
not assess the strength of the relationship between N. meningitidis A reported and the
MenAfriVac® immunization in African meningitis belt. The extended finding of this
study was the high degree of relationship between the reduction of N. meningitidis A
reported and the MenAfriVac® immunization in 21 out of the 26 countries of African
meningitis belt ( Phi = 0.657, P=0.000). Stuart (2018) and Trotter et al. (2017) also found
a 99% decline of N. meningitidis A in MenAfriVac® vaccinated countries. As with this
study, some authors found that after the introduction of MenAfriVac®, there was
predominance of other meningitis pathogens (N. meningitidis W135, N. meningitidis C,
N. meningitidis X, and Streptococcus pneumoniae) with the near disappearance of N.
meningitidis A in African meningitis belt countries (Diallo et al., 2017; LaForce et al.,
2017; PATH and WHO, 2016; Trotter et al., 2017).
N. meningitidis A epidemics reported by health districts before and after
MenAfriVac® introduction. The study found 99.6% decline of risk for a health district
to be in epidemic due to N. meningitidis A after the introduction of MenAfriVac®, (RR
0.004, 95% CI 0.001-0.016). This result confirmed findings of the literature
characterized by a disappearance of N. meningitidis A epidemics in MenAfriVac®
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vaccinated health districts (Diallo et al., 2017; Diomandé et al., 2015; GAVI, 2016;
Kristiansen et al., 2015; Meyer, 2017; Novak et al., 2012; Obaro et al., 2016; PATH and
WHO, 2016; Retchless et al., 2016; Sambo et al., 2015; Stuart, 2018; Trotter et al., 2017,
WHO, 2015a). However, the risk for a health district to report N. meningitidis A
epidemic after the introduction of MenAfriVac® was not found in the literature. Trotter
et al. (2017) observed a 59% decline globally in risk of a health district reaching
meningitis epidemic threshold. Stuart (2018) found that the number of all meningitis
epidemics at health district level has fallen by 60% following MenAfriVac® vaccination;
meningitis is caused by other meningococcal serogroups than A.
The results of the study confirmed those found in the literature. The multiple-level
approaches that are individual, relationship, community, organizational, and policy levels
of SEM as a theory-based framework fit with the findings of the study. MenAfriVac®
immunization campaigns implemented in 21 out of 26 African meningitis belt countries
to protect individuals and communities have achieved one of the main objectives of the
meningitis control program, to eliminate meningitis epidemics caused by N. meningitidis
A. The results of this study show near elimination of N. meningitidis A epidemic with a
99.6% decline of risk for a health district to report N. meningitidis A epidemic.
MenAfriVac® unvaccinated individuals and communities living in high-risk areas of N.
meningitidis A epidemic are vulnerable. Therefore, prevention using MenAfriVac®
immunization was relevant to provide individual protection and herd immunity against N.
meningitidis A.
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Limitations of the Study
To measure the effects of a new vaccine, surveillance was relevant because it
provided high validity and reliability. Data and information used in this study were
accurate. This study retrieved accurate data from meningitis surveillance and
immunization from WHO IST WA database. The 21 African meningitis countries
involved in this study have used appropriately the case definition of meningitis and the
standard operating procedures for testing CSF samples. The adequate use of standard
operating procedures for meningitis surveillance including testing CSF samples
contributes to the validity of meningitis surveillance. Meningitis surveillance
implemented by most of the countries in the African meningitis belt demonstrate
timeliness, representation, sensitivity, and specificity. However, for a few countries, there
were missing data. Fortunately, the missing data from countries were not significant at
slightly under 2.5%. External validity requires a sound definition of the sample group and
its environment that include demographic data from surveillance. This study met this
condition.
The generalizability of this study is feasible due to the large sample size from the
21 countries chosen for this study out of 26 countries of the African meningitis belt. The
total estimated population of the 21 African meningitis belt countries was 407,958,506
persons at highest risk of meningitis. Between 2010 and 2017,286,995, 073 persons aged
1-29 years old living in 1,713 health districts were immunized with MenAfriVac® with
100% administrative coverage achieved. The target population of this study was large
and representative because a nonprobability sampling method was used and the minimum
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sample size was 144 calculated using G*Power 3.1.9.2. Therefore, the findings of this
study can be generalized.
Recommendations for Future Research and Practice
The purpose of this study was to fill the gaps in the literature by assessing the
effects of MenAfriVac® in more countries and several years after the introduction in
2010 than the previous studies. This study provided more information on the relationship
between MenAfriVac® introduction and the CFR, the strength of the relationship between
MenAfriVac® introduction and N. meningitidis A, and also established the relationship
between the introduction of MenAfriVac® and the occurrence of epidemics caused by N.
meningitidis A. To evaluate the effectiveness of the introduction of MenAfriVac®, the
study used meningitis enhanced surveillance data from 2004 to 2017, and immunization
coverage between 2010 and 2017. This multi-country study involved 21 out of the 26
countries of African meningitis belt that introduced MenAfriVac®. People living into the
1,713 meningitis highest risk health districts were involved. The study also helped to
assess more year’s protection provided by MenAfriVac® and showed the risk of the
occurrence of meningococcal meningitis due to other serogroups than N. meningitidis A.
The study found that the introduction of MenAfriVac® in African meningitis belt
reduced significantly the incidence rate of the meningitis suspected cases, the meningitis
CFR, deaths due to meningitis disease, and epidemics caused by N. Meningitidis A.
Before 2010, N. meningitidis A was predominant. The study also showed that after the
introduction of MenAfriVac® since 2010 until 2017, the predominant meningitis
pathogens were S. Pneumoniae, N. meningitidis W135, and N. meningitidis C. N.
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meningitidis represent almost 62.06% out of all meningitis pathogens laboratoryconfirmed between 2010 and 2017. Based on the existent gaps in the literature, pertinent
findings statistically significant provided by the study, and the limitations of this study,
few relevant recommendations on practice and future studies were developed.
Concerning research, the first recommendation is to conduct in future a
longitudinal study that permits long-term follow-up of people vaccinated with
MenAfriVac®. This study was a quantitative retrospective study such as those conducted
using enhanced surveillance on the same topic (Lingani et al.,2015; Djingarey et al.,201;
Diomandé et al., 2015; Novak et al., 2012; Diallo et al., 2017; Trotter et al., 2017). Few
longitudinal studies using antibodies determination and carriage were done showing early
effects of MenAfriVac® (Kristiansen, 2012; Kristiansen et al., 2013; Collard et al., 2013;
Daugla et al., 2013). One of the limitations of this study and the others that used
retrospective data cited above is the lack of control over data. A longitudinal study, for
example, a cohort study will involve people living in high-risk districts vaccinated with,
and the occurrence of meningitis and deaths caused by N. meningitidis A among them.
The control of data by an investigator will be better and missing data will be probably
reduced.
The second recommendation is to conduct more studies on the relationship
between the effects of the introduction of MenAfriVac® and the meningitis mortality and
CFR. CFR is pertinent because it might demonstrate the gravity of disease, the effects of
the case management, the awareness of the population on the disease, and the health care
system and policies to respond to the disease. The high level of CFR may contribute to
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improve or adjust public health policies to inverse the situation. The study showed 46%
of reduction of CFR after the introduction of MenAfriVac®. The majority of the studies
conducted provided results on meningitis deaths. Few studies conducted by Novak et al.
(2012), Diallo et al. (2017), and WHO (2016) showed the relationship between
MenAfriVac® and the meningitis mortality and CFR.
The third recommendation concerns the research and development of an
affordable multivalent polysaccharide conjugate vaccine against N. meningitis (A, C,
W135, X, Y). The findings of this study as the literature showed the predominance of
other pathogens than N. meningitis A, after the introduction of MenAfriVac®. These
pathogens are N. meningitidis W135, N. meningitidis C, N. meningitidis X, and
Streptococcus pneumoniae (PATH and WHO, 2016; Diallo et al., 2017; Trotter et al.,
2017; LaForce et al., 2017). The existent multivalent polysaccharides are not affordable
for African countries, and the vaccine against N. meningitidis X is not yet developed.
Therefore, the research and development of an affordable multivalent polysaccharide
conjugate vaccine against N. meningitis (A, C, W135, X, Y) are pertinent because it will
help to eliminate meningococcal disease representing 55% of meningitis disease in
Africa.
Concerning the practice, the fourth recommendation is to update the risk
assessment of the meningitis status after the introduction of MenAfriVac® in all the 26
countries of meningitis belt. The risk assessment conducted on N. meningitis A showed
that people were living in 1,713 meningitis highest risk health districts out of 3,817 of the
26 countries of African meningitis belt. Lapeyssonnie (1963) described for the first time
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African meningitis with 22 high-risk countries. With findings of Greenwood (1999)
establishing endemicity, four new countries were added in 1987. Following the
introduction of MenAfriVac®, the meningitis bacterial profile and level of risk due to
meningitis disease might change. The changes can be explained by the current
distribution and profile of the predominant pathogens found that are N. meningitidis
W135, N. meningitidis C, N. meningitidis X, and Streptococcus pneumoniae, and the
reduction of N. meningitidis A (PATH and WHO, 2016; Diallo et al., 2017; Trotter et
al., 2017; LaForce et al., 2017). The results of the future risk assessment will help to
improve public health policies, and review strategies to eliminate meningitis as a burden
in Africa.
The fifth recommendation is to continue to improve meningitis enhanced
surveillance to avoid missing data. Even though technical partners as WHO and CDC
support countries to provide complete and accurate data, there are few countries that
should improve meningitis enhanced surveillance. Especially reinforce the completeness
rate. This study retrieved accurate secondary data from WHO data base with almost 2.5%
missing data. This situation would have been less or null if the enhanced surveillance was
improved especially the completeness in following Guinea Bissau, Guinea, Mauritania,
South Sudan, and Uganda.
The sixth recommendation is to improve public health policies on immunization
and enhanced surveillance to ensure sustainable high immunization coverage and high
quality of enhanced surveillance. WHO. The MenAfriVac® herd protection and
individual protection become while health district obtains at least 90% of administrative
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coverage or 70% of immunization coverage from the independent coverage survey.
Therefore, one of the objectives of the vaccination mass campaign is for each health
district to reach at least 90% of administrative coverage. CAR obtained 88%
MenAfriVac® coverage, the other 20 countries selected for this study achieved 90% and
more of MenAfriVac® coverage. The data provided by meningitis enhanced surveillance
and used in this study showed a significant reduction of risk of reporting N. meningitis A
in all the 21 countries. The MenAfriVac® high coverage was explained by the relevant
organization of vaccination mass campaigns in the countries that introduced
MenAfriVac® (Djingarey et al., 2012; Djingarey et al., 2015; WHO, 2017 March 13).
Therefore, it is pertinent to reinforce public health policies on immunization and
enhanced surveillance to ensure sustainable high immunization coverage and high quality
of enhanced surveillance.
Social Change Implications
The positive social change demonstrated in the study was firstly the high quality
of organization and implementation of MenAfriVac® immunization that provided high
immunization coverage. The high immunization coverage was adequate for individual
and herd protection in health districts that introduced MenAfriVac®. The second positive
social change demonstrated by the study was the use of high-quality meningitis
surveillance as a public health intervention to assess the effectiveness of MenAfriVac®
into the meningitis belt. These positive social changes fit the SEM because they take into
consideration the protection through prevention with the multiple-level approaches that
are individual, relationship, community, organizational, and policy levels.
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It is valuable to build strong health policies based on evidence that will contribute
to achieve public health problems as vaccine-preventable disease including meningitis.
The findings of this study will create a positive social change fostering countries to
improve immunization and meningitis surveillance policies to maximize MenAfriVac®
coverage and the performances of meningitis surveillance respectively. The improvement
of meningitis surveillance will help to detect earlier meningitis epidemics and master
distribution and profile of pathogens.
The high MenAfriVac® coverage and the performant meningitis surveillance are
the main factors that determined achievement of near elimination of N. meningitidis A.
The study demonstrated that high MenAfriVac® coverage and enhanced surveillance are
pivotal to reduce the meningitis burden. Results will be used to inform policy and public
health practice to reduce the meningitis cases and improve quality of live in the
community..
Conclusions
Meningitis disease including meningococcal infection remains a burden in the 26
African meningitis belt countries (WHO, 2015a). The purpose of the study was to assess
the effects of the introduction of MenAfriVac® in African meningitis belt countries. For
this study 21 out of the 26 African meningitis belt countries were chosen. The period of
assessment was between 2004 and 2017 including the introduction of MenAfriVac®
from 2010 to 2017. The study contributed to answering all the four questions selected.
The results of the study confirmed the finding of the literature with few non-significant
difference. The study provided additional research evidence. Firstly, on the difference of
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CFR before and after the introduction of MenAfriVac®. Secondly, the study provided
other research evidence of literature was the high strength of the relationship between the
N. meningitidis A reported and the MenAfriVac® immunization coverage. Thirdly, the
study also showed the effects of the introduction of MenAfriVac® within the longest
period in all the 21 countries that introduced MenAfriVac® between 2010 and 2017.
The study showed the effectiveness of introduction of MenAfriVac® in African
meningitis belt. The key findings of the study indicated that meningitis disease is
reducing since the introduction of MenAfriVac®, meningitis deaths as well. The severity
of meningitis disease is also decreasing after the introduction of MenAfriVac®. The high
CFR 10% and over with 46% decline after the introduction of MenAfriVac® that can be
explained by the improvement of interventions against meningitis disease and the change
of treatment protocol with ceftriaxone that is used since 2014. The study also found a
high degree of relationship between N. meningitidis A reported and the MenAfriVac®
immunization in 21 out of the 26 countries of African meningitis belt between 2010 and
2017. The cases and epidemics of N. meningitidis A in African meningitis belt countries
that vaccinated have declined significantly following the extensive roll-out of
MenAfriVac®. The findings showed that N. meningitidis A is being eliminated. Despite
the fact that the cases significantly decreased, it still a threat, and the bacterial profile
changed with the predominance of N. meningitidis (C, W135, X, Y) and S. pneumoniae
that have continued to cause epidemics.
The vaccination coverage obtained during campaigns were high and contributed
to reducing N. meningitidis A cases and epidemics. The multiple-level approaches of
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SEM that are individual, relationship, community, organizational and policy levels fit
with the findings of the study. This study showed that the achievement of high
MenAfriVac® immunization coverage reduced N. meningitidis A cases and epidemics.
The study demonstrated that high MenAfriVac® coverage and enhanced surveillance are
pivotal to reduce the meningitis burden. Results will be used to inform policy and public
health practice to reduce the meningitis cases and improve quality of live in the
community.
Considering the existent literature, findings on the effects of the introduction of
MenAfriVac® in the meningitis belt, and the limitations of this study, few researches
should be done in future. These studies should be conducted on: the long-term follow-up
of people vaccinated with MenAfriVac®, update of the risk assessment on the meningitis
status after introduction of MenAfriVac® in all the 26 countries of meningitis belt, the
factors to improve meningitis enhanced surveillance, the effects of the introduction of
MenAfriVac® and the meningitis mortality and CFR, the development of affordable
multivalent polysaccharide conjugate vaccine against N. meningitis (A, C, W135, X, Y),
and on how to improve public health policies on immunization and enhanced surveillance
to ensure sustainable high immunization coverage and high quality of enhanced
surveillance.
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